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Autism spectrum condition (ASC) is a complex neurodevelopmental disorder that 
impacts physiological processes, cognition, functional behaviors, social-communication, 
and often has comorbidities. One approach gaining empirical support for ASC treatment 
is neurofeedback. Neurofeedback uses operant conditioning to normalize cerebral activity 
through auditory and visual reinforcement. Live Z-score Training (LZT) has become the 
latest advancement in neurofeedback.  There is no published research to date on LZT 
neurofeedback in adulthood ASC. The purpose of this study was to evaluate LZT’s 
impact on neuropsychological measures in an adult with ASC. A multiple baseline 
single-case research design was used with a convenience sample of one adult with ASC 
to evaluate the effects of 20 LZT sessions using the Conservative Dual Criterion visual 
inspection method as the primary form analysis. ADHD, mood stability, anxiety, 
depression, and ASC symptoms were significantly reduced according to the Neuropsych 
Questionnaire. The participant improved significantly on the CNS Vital Signs (CNVS) 
Neurocognitive measures of executive function, cognitive flexibility, reaction time, and 
complex attention. Also, the participant increased intelligence as measured by the Test of 
Nonverbal Intelligence.  Lastly, the participant had changes in brain function according to 
quantitative electroencephalography and low-resolution brain electromagnetic 
tomography. CNVS processing speed was the only measure that did not significantly 
change. No adverse effects were reported. This study may lead to positive social change 
by providing a technologically advanced intervention for adults with ASC, which may 
improve their overall quality of life and promote self-sufficiency through adulthood. 
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Chapter 1: Introduction 
Introduction to the Study 
The purpose of this study is to explore the efficacy of neurofeedback Live Z-score 
Training (LZT) in improving overall neuropsychological functioning in an adult who has 
an autism spectrum condition (ASC).  The American Psychiatric Association Diagnostic 
(APA) Statistical Manual Fourth Edition Text Revised (DSM-IV-TR; 2000) categorized 
ASC in the following mental disorders: autistic disorder, Asperger’s disorder, childhood 
disintegrative disorder, and pervasive developmental disorder not otherwise specified.  
Most recently, the APA (2010) has considered autism as a spectrum disorder, including 
the subtypes under one unified label.  The proposed change will still maintain the two 
core symptoms of autism: stereotypic behaviors/obsessive narrowed interests and social-
communication impairment.  Although diagnosed in childhood and considered a part of 
the childhood mental disorders in the DSM-IV-TR, autism is a neurodevelopmental 
disability with impairments that persist in adulthood (APA, 2000, 2010).  Despite the 
lifelong impact of ASC, intervention researchers largely focused on children and 
adolescents and have not been validated in adult samples (Roy, Dillo, Emrich, & 
Ohlmeier, 2009).   
The principal investigator plans to evaluate the effects of neurofeedback on 
measures of neuropsychological functioning in an adult with ASC, an area that has not 
been well researched (Coben, Linden, & Myers, 2010).  Neurofeedback has demonstrated 
effectiveness in treating children with ASC through improved neurophysiological 
functioning, executive functioning, and decreased autistic symptoms (Coben & Padolsky, 





adults with ASC (Thompson & Thompson, 2010).  Thompson and Thompson published 
this retrospective report reviewing the effect of a combination of neurofeedback and other 
interventions in 12 adults with ASC (Thompson, Thompson, & Reid, 2010b).  Earlier, the 
same authors published qualitative case studies of adults with ASC in a textbook on 
neurofeedback (Thompson & Thompson, 2003).  It is necessary to further investigate 
neurofeedback in adults with ASC in order to better understand the efficacy of 
neurofeedback in older age groups, with consideration for changes of neuroplasticity with 
age.  
Quantitative research on neurofeedback in adults with neurodevelopmental 
disorders will be an important step to more fully evaluate the effects of such interventions 
in different stages of life. Further, there has not been a quantitative study investigating 
change related to a specific type of neurofeedback, LZT, which uses a normative 
database in real-time to individualize sessions (Collura, Guan, Tarrant, Bailey, & Starr, 
2010; Thatcher, 2008; Thatcher & Lubar, 2008). 
Background of the Study 
Since the mid-1980s, rates of ASC have continued to rise.  From only .4 in 1,000 
children being diagnosed in 1985 to 9 in 1,000 children by 2006 this increase identifies a 
great need for comprehensive evaluations and interventions early in childhood (Centers 
for Disease Control and Prevention [CDC], 2007, 2009).  Providing such services may 
reduce the scope of lifelong needs for services and aid in obtaining social independence.  
However, early interventions are often not available due to financial reasons, access to 
care, or treatment resources available (Symon, 2001).  Adults with ASC in particular are 





behavioral and neurological aspects of autism (Minshew, Sweeney, Bauman, & Webb, 
2005).  Adulthood interventions are further lacking in areas like assessment and for 
research that addresses the ongoing deficits that impact global functioning such as ability 
to obtain and maintain employment (Shea & Masibov, 2005).  The need to validate 
effective interventions for adults with ASC is critical to offsetting pervasive service needs 
throughout adulthood (Wolf & Paterson, 2010). 
Problem Statement 
 The main research problem addressed in this study is that autism researchers have 
mainly focused treatment for ASC in childhood (Roy et al., 2009; Wolf & Paterson, 
2010).  Specifically, Coben et al. (2010) suggested that neurofeedback is effective in 
children with ASC; however, what is missing in the literature are data regarding how 
neurofeedback may be related to neuropsychological change in adults with ASC.  No 
researchers have focused specifically on ASC in this age group despite the need for long-
term interventions.  Adults with ASC, who are often in need of lifelong supports because 
of developmental delays, are largely ignored in the literature (APA, 2000; Wolf & 
Paterson, 2010).  Problems like gainful employment, independent living, relationships, 
and comorbid conditions such as anxiety disorders complicate the concerns for adult 
individuals with ASC (Shea & Masibov, 2005).  Most importantly, researchers need to 
determine if interventions found effective in childhood are associated with 
neuropsychological change in adulthood (Coben et al., 2010).  Also, interventions may be 
associated with improvement in neuronal development throughout a lifetime (Jones, 
2004; Malkowicz & Martinez, 2009; Pinel, 2008).  Furthermore, neuroplasticity in 





same interventions effective in childhood are related to improved neuronal functioning 
and neurocognitive abilities in adults.   
Purpose of the Study 
The purpose of this single-case research study was to evaluate the effect of 
neurofeedback LZT on neuropsychological symptoms, core autistic symptoms, 
neurocognitive abilities, intelligence, and neurophysiological functioning in an adult with 
ASC identified through a local neurofeedback clinic.  Few studies investigating change 
associated with interventions specifically addressing ASC symptoms in adults have been 
conducted (Roy et al., 2009), and it may be expected that treatments found effective in 
children and adolescents may be associated with similar changes in adulthood.  However, 
there have been no studies evaluating neurofeedback LZT for adults with ASC. Lastly, 
this study may enhance the need to explore use of single-case research as an effective 
methodological approach for smaller and unique populations like adults with ASC, 
particularly in rural areas.   
Nature of the Study 
The single-case research study will consist of a convenience sample of an adult 
participant, over the age of 18, diagnosed with ASC recruited from rural northern 
Michigan neurofeedback clinic.  The clinic was responsible for distributing the 
advertorial to prospective clients who met the research criteria.  The participant had a 
preexisting diagnosis of ASC identified by a qualified healthcare/educational 
professional.  The clinic was responsible for providing a minimum of 16 sessions of 
neurofeedback LZT to the prospective client with ASC.  The research study consisted of 





nonverbal intelligence, quantitative electroencephalogram (QEEG), and observation of 
side effects, which were conducted during a baseline phase and neurofeedback phase, 
also referred to as an AB approach through visual inspection analyses.  
Research Questions and Hypotheses 
1. Is neurofeedback LZT related to the change in the core symptoms of autism in 
an adult with ASC? 
H01: μ1 = μ2 –There will be no significant differences in autism symptoms as 
measured by the Neuropsych Questionnaire, Long Form (NPQ-LF) during the baseline 
and neurofeedback phases in a participant who receives 20 sessions of neurofeedback 
LZT.   
H11: μ1 > μ2 –There will be a significant decrease in autism symptoms as 
measured by the NPQ-LF between the baseline and neurofeedback phases in a participant 
who receives 20 sessions of neurofeedback LZT.    
2. Is neurofeedback LZT related to a significant reduction in neuropsychological 
symptoms associated with attention, impulsivity, anxiety, depression, and mood stability 
of an adult with ASC? 
H02: μ1, μ2, μ3, μ4 = μ6 , μ7, μ8, μ9  –There will be no significant differences in 
ADHD, Anxiety, Depression, and Mood Stability indices as measured by the NPQ-LF 
during the baseline and neurofeedback phases in a participant who receives 20 sessions of 
neurofeedback LZT.   
H12: μ1, μ2, μ3, μ4 > μ6 , μ7, μ8, μ9 –There will be significant decreases in ADHD, 





the baseline and neurofeedback phases in a participant who receives 20 sessions of 
neurofeedback LZT.  
3. Is neurofeedback LZT related to a significant improvement in neurocognitive 
abilities in executive functioning and processing speed in an adult with ASC? 
H03: μ1, μ2= μ3, μ4 –There will be no significant differences in executive 
functioning and processing speed as measured by the CNS Vital Signs (CNSVS) 
Neurocognitive Test between the baseline and neurofeedback phases in a participant who 
receives 20 sessions of neurofeedback LZT.   
H13: μ1, μ2 < μ3, μ4 –There will be significant increase in executive functioning 
and processing speed as measured by the CNSVS Neurocognitive Test between the 
baseline and neurofeedback phases in a participant who receives 20 sessions of 
neurofeedback LZT.     
4. Is neurofeedback LZT related to significant improvement in overall nonverbal 
intelligence in an adult with ASC? 
H04: μ1 = μ2 –There will be no significant difference in general intelligence as 
measured by the Test of Nonverbal Intelligence (TONI) between baseline and post-test 
quotient scores in a participant who receives 20 sessions of neurofeedback LZT.   
H14: μ1 < μ2 –There will be a significant increase in general intelligence as 
measured by the TONI from baseline to post-test quotient scores in a participant who 
receive 20 sessions of neurofeedback LZT.   






 H05: μ1 = μ2 –There will be no significant differences in neurophysiological 
functioning as measured by QEEG based on the Applied Neuroscience, Inc. (ANI) 
Dynamic Link Library (DLL) and low brain resolution electromagnetic tomography 
(LORETA) statistical software in a participant who receives 20 sessions of 
neurofeedback LZT.   
H15: μ1 < μ2 – There will be significant changes in neurophysiological functioning 
as measured by QEEG based on the ANI DLL and LORETA statistical software in a 
participant who receives 20 sessions of neurofeedback LZT.   
Theoretical Base 
Neurofeedback is the newest biofeedback modality that utilizes an 
electroencephalogram (EEG) in order to modify brain states for improved psychological, 
neurocognitive, and neurophysiological functioning (ISNR Board of Directors, 2009).  
Neurofeedback is based on modifying brainwaves in the learning theory paradigm, 
specifically in operant and classical conditioning (Thompson & Thompson, 2003).  
Operant conditioning is considered the main behavioral learning approach in the core 
textbooks on neurofeedback (Demos, 2005; Thompson & Thompson, 2003).  Operant 
conditioning is essentially the concept that a reinforcing stimulus increases the likelihood 
of the temporally associative behavior occurring again (Skinner, 1935, 1937, 1948, 
1950).  The Law of Effect is the basis for operant conditioning and most learning theories 
in that behavior increases when associated with a reinforcement or reward.  Specifically, 
neurofeedback is based on contingent reinforcers consisting of visual and auditory 
rewards (ISNR Board of Directors, 2009).  The feedback is temporally associated with 





example might be to increase higher frequency bandwidths like beta waves to improve 
attention.  Neurofeedback is also representative of behavioural classical conditioning 
(Thompson & Thompson, 2003).  For instance, pairing the training (unconditioned 
stimulus) and elicited brainwaves (unconditioned response) with a desired behavior such 
as reading (conditioned stimulus) will promote optimal brainwave activity (conditioned 
response) during this behavior when auditory or visual stimuli is no longer present 
(Thompson & Thompson, 2003).  In summary, neurofeedback consists of teaching the 
individual to self-regulate brainwaves through auditory and visual feedback.  The 
theoretical and historical influences of neurofeedback will be explored in more detail in 
Chapter 2.  
Definition of Terms 
General Terms 
Autism spectrum condition (ASC): Autism spectrum condition will be used 
throughout this dissertation in place of the diagnostic label of autism spectrum disorder 
(Baron-Cohen et al., 2005). 
Hyperserotonemia: Elevated serotonin levels identified in ASC (Anderson, 
Horne, Chatterjee, & Cohen, 1990). 
Neurophysiology: Study of physiological processes in neurons (Pinel, 2008). 
Neuroplasticity: Adaptation of neuronal connections in the central nervous system 
across the lifespan (Gynther, Calford, & Sah, 1998). 
Neurotransmitters: Chemical transmission from a neuron to a target cell through 
the synaptic cleft such as noradrenaline, dopamine, serotonin, and cholinergic and 





Quasi-experimental: Research approach that tests causal hypotheses through the 
comparison of the manipulation of an experimental group and absence of the 
manipulation in the control group using pretest and posttest measures without random 
assignment (Shadish, Cook, & Campbell, 2002). 
Theory of Mind: The ability to understand or predict the mental states in others 
(Leslie, 1987). 
Weak Central Coherence: Inflexible, maintaining sameness, the inability to draw 
information together, recalling details but not the whole context, or failing to understand 
changes in the context for appropriate behavior (Thompson et al., 2010a). 
Neurofeedback Terms 
 Asymmetry: A type of EEG connectivity measure that identifies the differences 
between signal amplitudes normalized to the sum of their amplitudes (Collura, 2008).  
 Amplitude: Height of the wave measured in microvolts-the variable that is 
changeable in neurofeedback (Demos, 2005; Thompson & Thompson, 2003; Townsend, 
2007). 
Bandwidth frequencies: The component bands for the Dynamic Link Library 
database consists of: Delta = 1-4 Hz, Theta = 4-8 Hz, Alpha = 8-12.5 Hz, Beta = 12.5-
25.5 Hz, Beta 1 = 12-15.5 Hz, Beta 2 = 15-18 Hz, Beta 3 = 18-25.5 Hz, and Gamma = 
25.5-30.5 (Collura, 2007).   
Coherence: A type of EEG connectivity measure that calculates the cross 
correlation of shared activity and morphology between frequencies of two or more sites 
(Thompson & Thompson, 2003). 





between various parts of the cerebral cortex (Collura, 2008). 
 Electroencephalography (EEG): A physiological recording measured with 
microvolts of post-synaptic potentials from pyramidal cells within the cerebral cortex to 
assess or use as a biofeedback intervention in neurological conditions such as epilepsy 
(Collura, 2008; Rowan & Tolunsky, 2003).  
 Frequency: Number of cycles per second measured in Hertz (Hz; Demos, 2005; 
Thompson & Thompson, 2003; Townsend, 2007). 
Hemoencephalography: The measurement of voluntarily-controlled regional 
blood flow in the brain through audio/visual feedback (Limsila et al., 2003). 
Hertz: Measurement of each cycle of EEG wave per second (Demos, 2005; 
Hammond, 2006; Thompson & Thompson, 2003; Townsend, 2007). 
Live Z-score Training (LZT): Software developed by Brainmaster using the 
Neuroguide database to compute z-scores in real time for assessment and neurofeedback 
training (Collura et al., 2010).   
Mu rhythms: Frequency band of 8-13 Hz over the sensorimotor cortex that is 
consistent with mirror neuron system with reduced mu power being associated with 
performing and observing actions critical for imitation and understanding other’s 
behaviors (Oberman et al., 2005). 
Neurofeedback: A form of biofeedback that uses an EEG amplifier to measure 
electrical activity from the cortex to monitor and change brain function related to 
behavioral, cognitive, and subjective experiences through audio and visual reinforcement 
(ISNR Board of Directors, 2009). 





when morphologically the same waves occur at the same time in two different sites 
(Thompson & Thompson, 2003).   
Quantitative EEG (QEEG): The processing of an EEG recording of typically 19 
sites and processed through statistical methods like Fast-Fourier Transformation (FFT) to 
quantify the power for each bandwidth or comparison of the record with a normative 
database which present results that show power, coherence, symmetry, or phase (Collura, 
2008; Hughes, & John, 1999). 
 Z score: A metric standardization that compares a score or measure with a 
population mean through the number of standard deviations from the mean (Collura, 
2007).  
 10-20 International System of Electrode Placement: The EEG system developed 
in the 1950s by Dr. Herbert Jasper to provide accurate measurements of the skull and 
landmarks using 10% and 20% of the total measurement to identify the 19 placements of 
EEG electrodes on three planes sagittal, coronal, and horizontal (Rowan & Tolunsky, 
2003). 
Assumptions 
The following assumptions apply to this study:  
 The use of neurofeedback will promote neuroplasticity of brain function in 
adulthood and serve as a way to develop new neuronal growth for complex 
neurological conditions like ASC (Malkowicz & Martinez, 2009).   
 Changes in the dependent variables assessed during baseline and 






The limitations of this proposed study are the specificity of the research questions, 
type of neurofeedback training, methodology and design, and experimenter bias.  
Neurofeedback has been argued as having several problems in methodology related to 
few randomized controlled trials, small sample sizes, and few longitudinal studies that 
support this approach (Rojas & Chan, 2005).  Within this study, all these concerns are 
present including assessing an individual participant rather than a whole sample, the 
inability of longitudinal assessment, and the lack of a control group.  Further, researchers 
have felt that there were few neurofeedback studies that provided adequate statistical 
analyses of effect size changes in cognitive, behavioral, and EEG measures (Rojas & 
Chan, 2005).  The limitations of neurofeedback research has been in large part due to 
preexperimental case study reports that have not utilized consistent measures that are 
reliable and valid for assessing the effect of neurofeedback.  For this study, however, a 
more stringent single-case research approach that provided multiple subjective and 
objective measures was used.  For instance, there was repeated baseline and treatment 
phase measures consisting of questionnaires rating symptom severity, neurocognitive 
testing, intelligence, and brain maps.  The variety of measures allowed for an in-depth 
exploration of changes in overall functioning.  This was the first neurofeedback LZT 
study to specifically evaluate broad neuropsychological changes in ASC in adulthood.   
Given this was a single-case research design there are a number of 
methodological concerns regarding the type of analysis and threats to external validity.  
Visual inspection served as the primary method to determine efficacy.  The use of visual 





threats to internal validity.  For instance, change may be the result of exposure to the 
assessment process in baseline and neurofeedback phases.  Also, visual inspection has 
been historically considered largely subjective; therefore, for this study an expectation to 
have a more reliable means to validating findings was required.  Therefore, the 
conservative dual criterion provided an improved visual inspection method, which has 
guarded against Type I and II error rates and higher power levels than statistical 
procedures (Fisher, Kelley, & Lomas, 2003).  Additionally, external validity of the 
findings may have been impacted by the N = 1 design in the study, pretest sensitization, 
type of setting, and awareness of symptoms that are being assessed with the expectation 
of benefit from the neurofeedback (Kazdin, 1982).   
Also, there was the possibility that the participant was highly motivated and had 
the expectation to see change through neurofeedback, which could then lead to elevated 
placebo responses.  This was guarded against using objective measures such as the QEEG 
and neurocognitive measures that are not influenced by subjectivity.  Finally, the 
participant was drawn from an inherently biased sample of European American males 
based on both the gender specificity in ASC and the rural area that will be sampled. The 
researcher encouraged the neurofeedback clinic to use nonbiased recruitment by not 
discriminating against any participants based on gender, race, or ethnicity.   However, the 
participant was a European American male. 
These limitations were detailed in Chapter 5 of this study.  The most critical 
element was the ability to generalize findings to the larger ASC population.  The issues 
with sample selection and the use of a single participant limited the exposure of the 





will be important to explore in neurofeedback LZT.  In addition, the sample from the area 
in which it was collected was explored in more detail.  This was considered a preliminary 
study into the role that it might play in adults with ASC.  In addition, the visual 
inspection method might be considered a limitation in the analysis of the data if the data 
is not clearly depicted.  For instance, the data in baseline may not have been stable, so it 
may have resulted in skewed regression line.  Concerns related to the analysis will be 
important to explore for future researchers who intend to use visual inspection as a 
primary analysis.  The principal investigator provided a minimum of five baseline 
measures to ensure adequate baseline and treatment phase data are provided, which 
provides enough data to determine significance based on the binomial formula (Fisher et 
al., 2003).  This may assist in future research in reducing the time or number of testing 
administrations.   
Delimitations 
The scope of this study is delimited by the potential to assess neuropsychological 
changes associated with neurofeedback LZT and generalize findings to the larger 
population of adults with ASC.  Single-case research avoids averaging group processes in 
the study, thus decreasing the risk of Type I errors (Kazdin, 1982).  Further, this study 
provides specific information on individual changes over time using neurofeedback LZT 
through visual inspection analyses.  Visual inspection has been argued as a more 
powerful way to show effects over statistical analyses that may find effects in very small 
changes (Kazdin, 1982).  It may be more applicable to the larger population if the 
participant is treated as their own control with a baseline and an experimental phase 





of multiple measures including neuropsychological symptoms, autistic symptoms, 
neurocognitive performance, intelligence, and brain function.   The repeated measures 
approach provided a stronger case for generalizing this research because there will be 
significantly more evidence to support change over time rather than simply pre and 
postmeasurements that are typical in between group studies. 
Significance of the Study 
The significance of the study lies in providing support in the literature for 
technological advancement of procedures that are being newly developed and 
implemented.  Most importantly, it supports the need to address developmental deficits 
across the lifespan within this ASC population.  A definite need has been identified to 
explore and validate interventions in adulthood as opposed to continuing only to provide 
research in earlier stages of development.  This study helps support the need to explore 
viable interventions like neurofeedback into adulthood and may also aid in the 
development of research that is able to employ more stringent randomized controlled 
treatment studies.  There have been no studies to date in research on the effects of 
neurofeedback LZT that utilize a quantitative approach in an adult with ASC.  To date, 
only qualitative case studies and retrospective reports with mixed interventions (e.g., 
metacognitive strategies and neurofeedback combined) have been researched (Thompson 
& Thompson, 2003, 2010).  Also, there is a great need for community mental health, 
hospitals and private clinics to provide and implement cutting edge interventions for ASC 
to more comprehensively address the complexity of the condition. Through this study, the 
research will promote utilization of tools to help adults with ASC optimize their life. 





Social Change Implications 
The social change implications for this study are twofold.  First, the principal 
investigator’s intention was to evaluate the effect of neurofeedback on 
neuropsychological measures.  The research will help to expand the literature regarding 
whether neurofeedback interventions are associated with neuropsychological change in 
adult ASC.   Second, there is a need to identify interventions that address the 
neuropsychological complexity of ASC in adults through behavioral and 
neurophysiological methods like neurofeedback.  It will assist in exploring issues such as 
adult neuroplasticity, the ability to generalize studies from children to adults, and better 
understand changes associated with neurofeedback.  The findings may also provide 
research-based rationale for insurance reimbursement consideration for neurofeedback 
services; neurofeedback is currently not covered by most insurance providers, forcing 
patients to pay out of pocket for these services. 
Summary and Transition 
The purpose of this single-case research study was to evaluate the effect of 
neurofeedback LZT on neuropsychological symptoms, core autistic symptoms, 
neurocognitive abilities, intelligence, and neurophysiological functioning in an adult with 
ASC identified through a neurofeedback clinic.  The single-case research study consisted 
of a convenience sample of an adult participant, over the age of 18, diagnosed with ASC 
recruited from rural northern Michigan by a local neurofeedback clinic.  The research 
findings will help to expand the literature regarding whether neurofeedback interventions 





Chapter 2 is a review of the literature on autism such as the diagnostic 
background, cognitive theories, genetic and neurophysiological issues, neuroimaging and 
neurological patterns, prevalence and costs associated with autism and autism in 
adulthood.   Chapter 2 is also an exploration of research on neurofeedback’s theoretical 
background, research of neurofeedback in ASC, longitudinal research, neurofeedback 
LZT case reports, number of sessions to identify an effect, potential adverse effects, and 
the need for further research in specific areas of neurofeedback in ASC.  Chapter 3 
provides a background in the single-case research design, the study’s setting, participant 
inclusion and exclusion, informed consent, confidentiality, data collection and analysis, 
instrumentation and materials, procedure in Phase A and Phase B, research questions and 
hypotheses, variables, and protection of the participant.  Chapter 4 is a review of the 





Chapter 2: Literature Review 
Introduction to Literature Review 
The literature review presents themes consisting of an overview of ASC with 
issues related diagnosis, neurocognitive deficits, neurophysiological phenotypes, 
prevalence rates, costs associated with level of care needs, and adult-related issues, 
particularly the lack of research.  Next, the history, background, and efficacy of 
neurofeedback for treating ASC, and LZT as a specific neurofeedback approach are 
addressed.  Research began in 2007 and continued into July 2010.  Articles were derived 
from the electronic database EBSCO HOST in PsycINFO, PsycARTICLES, 
PsycBOOKS, SocIndex, Military & Government Collection, CINAHL Plus with Full 
Text, MEDLINE, Academic Search Complete, Academic Search Premier, and ERIC.  
Other collection methods included the search engine Yahoo using a modified search in 
advanced settings to collect only Adobe PDF files.  The key terms were used in the 
Boolean format: “AND,” “OR,” or quoted text (e.g., “Asperger’s syndrome”).  Terms 
used were: autism, autistic, spectrum, Asperger’s syndrome, disorder, PDD, 
neurofeedback, neurotherapy, neurobehavioral therapy, EEG biofeedback, 
hemoencephalography or HEG, EEG, QEEG, fMRI, PET, blood perfusion, mental 
health, costs, financial, frontal lobe, temporal lobe, frontotemporal, epileptiform, 
epilepsy, dietary, nutrition, gastrointestinal, allergies, psychopharmacology, 
neuroplasticity, neurotransmitters, serotonin, dopamine, theory of mind, empathy, weak 
central coherence, and executive functioning.  Supplemental information was found from 
reference lists.  Finally, the principal investigator also collected journal articles and texts 





Overview of Autism Spectrum Conditions 
Diagnostic Background of Autism Spectrum 
According to the CDC (2009), children with ASC are most accurately identified 
at around age 36 months.  ASC includes the DSM-IV-TR (2000) categories of autistic 
disorder, Asperger’s disorder, and pervasive developmental disorder not otherwise 
specified (PDD-NOS).  The DSM-IV-TR also includes the diagnoses of childhood 
disintegrative disorder and Rett’s disorder.  Historically, these conditions were 
considered a form of childhood psychosis because of the similarities between 
schizophrenia and autism, including idiosyncratic behaviors, obsessive rumination, poor 
social interrelatedness, and flat affect (APA, 2000; Asperger, 1945; Kanner, 1943, 1944; 
Wing, 1981).  Kanner (1943, 1944) was the first to identify and conceptualize ASC in 11 
children who had similar deficits in social interaction, communication, and stereotypic 
behaviors.  Later, Asperger (1945) identified similar symptoms noted by Kanner but 
without language delays.   Nearly 40 years later, Wing (1981) further differentiated high 
functioning autism by identifying children who had autistic symptoms with normal 
language development up to age 3, a condition he called Asperger’s disorder.  Underlying 
symptoms of autism consist of social-communication deficits, repetitiveness, obsessions, 
stereotypies, or restricted patterns of behaviors (APA, 2000).  However, by including 
those with and without language impairments and providing the PDD, NOS label, many 
researchers in the field are concerned that the DSM has resulted in an overabundance of 
ASC diagnosis (Volkmar & Klin, 2005).  The concerns are partly due to the wide range 
of subjective interpretation that could result when making a diagnosis of PDD, NOS.  





with the recommendation to include all of the PDD conditions under one unified label, 
autism spectrum disorder (ASD).  Autistic disorder, childhood disintegrative disorder, 
Asperger’s disorder, and PDD, NOS are currently understood as a spectrum of varying 
levels of deficits associated with two main areas of dysfunction: social-communication 
and fixated interests or repetitive/stereotypic behaviors (APA, 2010). Rett’s disorder will 
be considered a separate medical condition and not included as a part of the spectrum 
(APA, 2010).  Although delays in language were formerly viewed as a differentiation 
between higher functioning and lower functioning autism, the new DSM will consider 
autism as a varying disorder on a spectrum rather than distinct categories between 
Asperger’s and autistic disorder.   
An additional change advocated for by APA (2010) is the age of diagnosis.  
Despite DSM-IV-TR expectations of a diagnosis in early childhood, social delays in ASC 
may present as late as adolescence (APA, 2010).  Psychosocial demands are less apparent 
in infancy and early childhood and may only be evident at a later date when the social 
demands exceed the adolescent’s abilities (APA, 2010).  These changes in diagnostic 
criteria may improve the understanding of what ASC truly is.  
Fundamentally, some of the core symptoms of ASC are associated with problems 
in nonverbal and verbal forms of social-communication and social-emotional reciprocity 
(APA, 2000, 2010).  These symptoms are apparent in limited appropriate peer-
relationships and interactions.  In the other core area, symptoms are associated with 
idiosyncratic behaviors such as stereotypic motor mannerisms (e.g., finger-wringing), 
repetitive verbal behaviors (e.g., echolalia), sensory behaviors (e.g., spinning), adherence 





2010).  Other comorbid symptoms consist of problems with poor attention, hyperactivity, 
self-injurious behaviors, sensory integration, aggression, abnormal eating habits, and 
neurocognitive deficits (APA, 2000).   
Contradictory to the DSM-IV-TR, ASC is often comorbid with other symptoms 
found in exclusionary disorders such as obsessive-compulsive tendencies, receptive-
expressive communication deficits, flat affect similar to schizophrenia, 
hyperactivity/impulsivity, and attention deficits (Volkmar & Klin, 2005).  Despite similar 
attributes to other disorders, the current diagnostic practice is to not diagnose conditions 
like attention-deficit hyperactivity disorder (ADHD), obsessive-compulsive disorder 
(OCD), communication disorders, or schizophrenia in the presence of ASC (APA, 2000).  
Nevertheless, researchers have historically found that pharmacological interventions such 
as neurostimulants have been effective in treating individuals with ASC who also 
struggle with poor attention, difficulty concentrating, and hyperactivity (Aman & 
Langworthy, 2000; Tsai, 1999).   There are also high rates of anxiety, depressive, and 
bipolar disorders among individuals with ASC, further complicating treatment course 
(Raja & Azzoni, 2008; Shtayermman, 2008). The current practices for differentiation 
recommended by the DSM have inherent problems in recognizing the complexity of ASC 
beyond the core symptoms with the trend of comorbidity in disorders like ADHD and 
OCD (Volkmar & Klin, 2005), social anxiety (Bellini, 2006), and depressive disorders 
(Shtayermman, 2008).  
Neurocognitive Theories 
ASC has been often associated with neurocognitive deficits that contribute to the 





from normative samples with impediments in empathy or theory of mind (TOM) tasks 
(APA, 2000; 2010; Baron-Cohen et al., 2005; Baron-Cohen, Leslie, & Frith, 1985, 1986; 
Lawson, Baron-Cohen, & Wheelright, 2004; Leslie, 1987; Leslie & Frith, 1990; 
Thompson et al., 2010a), weak central coherence (APA, 2000; 2010; Happe, 2005; 
Thompson et al., 2010a), and executive functioning (APA, 2000; Best, Moffat, Power, 
Owens, & Johnstone, 2008; Hill & Bird, 2006; Kouijzer, de Moor, Gerrits, Buitelaar et 
al., 2009; Knezevic, Thompson, & Thompson, 2009, 2010; Koshino et al., 2005; 
Kouijzer, de Moor, Gerrits, Congedo et al., 2009; Lawson et al., 2004; Pineda et al., 
2008; Rinaldi et al., 2008; Thompson et al., 2010a).  These problems are often associated 
with deficits in anterior regions of the cortex, which is associated with higher cognitive 
abilities like emotional reciprocity, seeing the whole picture, and executive functioning 
(Thompson et al., 2010a).  Because of these problems, individuals with ASC are in need 
of interventions like neurofeedback that improve neurocognitive functioning (Thompson, 
Thompson, & Reid, 2010b). 
According to the APA (2000, 2010), one of the primary symptoms of ASC is a 
qualitative impairment in social interactions related to mutual interest, understanding 
others intentions, empathy, emotional reciprocity, and the underlying concepts of TOM.  
Empathizing deficits are consistent with problems in reciprocating communication, 
difficulty in predicting the thoughts and feelings of others, interpreting abstract emotions 
of others, difficulty in predicting the thoughts and feelings of others, and an appearance 
of social insensitivity (Baron-Cohen et al., 2005; Lawson et al., 2004).  Empathy and 
TOM are critical issues for individuals with ASC in regard to difficulty with pretend 





actions of others, or maintaining social responses to others based on mental states (Baron-
Cohen et al., 1985, 1986; Lawson et al., 2004; Leslie, 1987; Leslie & Frith, 1990).     
Developmentally, toddlers with ASC have problems with shared nonverbal 
communication and reflective facial expressions as early as 12 to 14 months (Baron-
Cohen et al., 2005).  Normal developing infants and toddlers from 18 to 24 months are 
able to understand emotional expression from others through intonation, facial 
expressions, and other nonverbal communication skills associated with empathy and 
TOM. Later in childhood, children develop a basis of early attachment through caregivers 
and eventually engage in larger contextual socialization outside their family of origin 
with peers (Premack & Woodruff, 1978; Wimmer & Perner, 1983).  Even children with 
Down’s syndrome are more capable than children with ASC in completing tasks of 
empathy and identifying mood states (Baron-Cohen, 1989); children with autism are 
unable to commit to unreal or imaginative aspects of cognition, such as drawing an unreal 
house (Scott & Baron-Cohen, 1996).  Advanced levels of TOM include the ability to 
process intonation and nonverbal facial cues of emotion (Hobson, 1986 a,b), and these 
are specific deficits in ASC that persist from childhood into adulthood (Kleinman et al., 
2001).  TOM does add to the social referencing model of attachment theories and 
provides a perspective on ASC core symptom (Leslie & Frith, 1990).   
Another major neurocognitive deficiency in ASC is described by weak central 
coherence (WCC; APA, 2000; 2010; Happe, 2005; Thompson et al., 2010a).  The WCC 
theory suggests that individuals with ASC are more apt to focus on details rather than 
integrating information as a whole (Happe, 2005).  Recall will tend to have unessential 





likely the result of hyperfocused areas of interest or seeing only the parts rather than the 
whole picture (Baron-Cohen et al., 2005).  Focusing on details may result in rigidity and 
obsessive behaviors where individuals are unable to switch attention to another area of 
focus, and it also accounts for the inability to understand or shift to different rules when 
the context changes (Thompson et al., 2010a).  WCC explains the specialized skills 
individuals with ASC tend to have, such as memorization of numbers or musical 
inclination (Happe, 2005).  Individuals with autism are often seen to have interest in 
system details and pursue careers in engineering, building, clocks, machines, puzzles, or 
computers, which are often obsessive interests in ASC (Baron-Cohen, et al. 2005).  There 
is also a need for structure, routine, and regimented activity (Lawson et al., 2004).   
Although TOM and WCC provide frameworks for the cognitive styles of ASC, 
there are few testing methods outside of checklists to evaluate them (Baron-Cohen, 
Wheelwright, Hill, Raste, & Plumb, 2001).  Alternatively, executive functioning has a 
variety of testing measures that have been assessed in ASC, which have also helped to 
evaluate the efficacy of interventions like neurofeedback (Knezevic et al., 2009. 2010; 
Kouijzer , de Moor, Gerrits, Buitelaar, et al., 2009; Pineda et al., 2008).  Significant 
problems have been found in cognitive flexibility, speed of processing, goal setting, 
attentional control, and other executive functioning areas in neuropsychological testing in 
participants with ASC (Knezevic et al., 2009, 2010; Kouijzer, de Moor, Gerrits, 
Buitelaar, et al., 2009).  Neurocognitive impairment in executive functioning tasks like 
response initiation, intentionality, planning, impulse control, working memory, and 
cognitive flexibility have been extensively researched in ASC (APA, 2000; Hill & Bird, 





Congedo et al., 2009; Knezevic et al., 2009. 2010; Koshino et al., 2005; Pineda et al., 
2008; Rinaldi et al., 2008).  The diagnostic formulation for ASC identifies a high 
comorbidity of symptoms related to executive functioning such as attention deficit, 
impulsivity, mood dysregulation, and cognitive inflexibility (APA, 2000).  For 
individuals with high functioning ASC, functional magnetic resonance imaging (fMRI) 
research suggests that while completing mental rotation tasks participants showed 
impaired performance in attention, cognitive control, and visual-spatial processing 
deficits compared to controls (Silk et al., 2006).   
Research methods have included the Tower of London (TOL; Just, Cherkassky, 
Keller, Kana, & Minshew, 2007; Knezevic et al., 2009, 2010) and Test of Variable 
Attention (TOVA; Pineda et al., 2008).  The TOL measures executive functioning 
through assessing problem solving skills.  Individuals with ASC were impaired in their 
performance on the TOL and significantly different from a normative control group in 
functional brain imaging (Just et al., 2007).  Another study using the TOL concluded that 
individuals with ASC were significantly impaired in planning efficiency, working 
memory, cognitive flexibility, and inhibition (Knezevic et al., 2009, 2010).  Pineda et al. 
(2008) found that a sample of children with ASC performed poorly in attention and 
cognitive control on the Test of Variable Attention (TOVA), a continuous performance 
executive functioning task.  There is evidence that male participants tend to have 
executive functioning deficits in areas like cognitive flexibility and strengths in analyzing 
systems and disembedding tasks (Best et al., 2004).  In this regard, autism has also been 
considered an extreme form of the male brain.  Overall, these studies exhibit significant 





neurocognitive deficits.   
Genetic and Neurochemical Abnormalities 
Autism is a complex neurodevelopmental condition consisting of multiple factors 
that influence the degree of impairment of the core autistic symptoms.  From genetic 
abnormalities (Caglayan, 2010; Cook, 1998) to irregular neurochemical processes 
(Anderson, & Hoshino, 2005), the heterogeneous nature of ASC has evolved over the 
past 20 years with advancement in neuroimaging and biogenetics technology.   
Heredity has been a major factor in setting the stage for autism.  The risk rates for 
monozygotic twins as high as 60%, and siblings having a 45 to 90 times greater 
likelihood of developing an ASC noted in one study (Cook, 1998).  A more recent review 
has found that there are rates as high as 95% in monozygotic twins (Caglayan, 2010).  
First degree relatives were found to have psychiatric disorders such as depression, OCD, 
and other anxiety disorders that are associated with serotonin abnormalities (Devlin et al., 
2005), which are also comorbid in ASC (APA, 2000).   
Given this familial tendency, genes likely play a significant role in the 
development of autistic symptoms.  For the past decade, independent study groups have 
been formed to define chromosomal abnormalities in ASC and to develop phenotypes 
that categorize variants on the spectrum (Cook, 1998).  Genetic research reviews have 
concluded that several genes may account for autism, such as single chromosome 
abnormalities in Fragile X or Turner’s syndrome (Cook, 1998), and other genetic 
disorders comorbid with ASC like Klinefelter, Rett, Prader-Willi, Timothy, 
Phenylketonuria, and Angelman syndromes (Caglayan, 2010).  The X chromosome may 





(Klin, McPartland, & Volkmar, 2005).  Chromosomal abnormalities with 17q11.1-q12 
impair tryptophan synthesis, resulting in hyperserotonemia and abnormal metabolic 
processes that are critical for normal neuronal development (Devlin et al., 2005; 
Tordjman et al., 2001).   Abnormalities with the short allele on the serotonin transporter 
gene will result in increased severity of social-communication deficits (Tordjman et al., 
2001).  Besides serotonin, there are other polymorphisms that impair dopamine and 
norepinephrine transmissions on chromosome 9q34, which results in the deficiencies 
seen in autism (Polleux & Lauder 2004).  
Genetic influences impact both neurochemical processes and neuronal 
development in ASC (Anderson & Hoshino, 2005).  Atypical neurologic development is 
concordant with the dysregulation of serotonin, dopamine, hypothalamic-pituitary-
adrenal functioning, and complications can arise from chemicals like exorphins 
(Anderson & Hoshino, 2005).  Neurochemical aspects of ASC were researched as early 
as 50 years ago by Schain and Freedman (1961), who identified abnormally high levels 
of serotonin or hyperserotonemia in autism with up to one-third of the ASC sample 
having this abnormality (Anderson, Horne, Chatterjee, & Cohen, 1990).  
Hyperserotonemia has been found to trigger an autoimmune response that results in high 
titers of autoantibodies furthering abnormal neuronal development (Burgess, Sweeten, 
McMahaon, & Fujinami, 2006).  Children with ASC have been found to have elevated 
epinephrine and norepinephrine plasma levels, and lower platelets for epinephrine, 
norepinephrine, and dopamine (Launay, Burszteijn, Ferrari, & Dreux, 1987).  The 
abnormal levels of neurotransmitters may result in the comorbid symptoms of ASC: 





perceptual distortions, obsessiveness, and social cognitive problems (Anderson & 
Hoshino, 2005; Ernst, Zamatkin, & Lancet, 1997).  Other neurochemicals related to ASC 
consists of components of the neuroendocrine system including glucocorticoid cortisal, 
gamma-aminobutyric acid, histidinemia, and phenylketonceria (Anderson & Hoshino, 
2005).  In addition, oxytocin has been identified as being dysregulated in ASC as well, 
and is related to the underlying problems in early attachment and social bonding 
(Hollander et al., 2007). 
With these genetic and neurochemical influences, the underlying structural 
development of the brain in autism is associated with problems such as accelerated 
neuronal development in the frontal lobe in as early as 28 weeks of life (Minshew et al., 
2005).  Because serotonin is critical for creation of synapses and neuronal differentiation, 
hyperserotonemia in autism leads to irregular sleep, body temperature, appetite, 
hormones, mood, and diminished neuroplasticity (Anderson & Hoshino, 2005; Chugani, 
2002; Tsai, 1999).  Specifically, serotonin synthesis from ages 2 to 11 has been 
calculated to be around 1.5 times more than typical adult levels of serotonin, which 
ultimately hinders growth in thalamocortical, sensory cortices, and subcortical structures 
such as the hippocampus and amygdala; these all are critical for communicating with the 
cerebral cortex in social memory and social language processing (Baron-Cohen et al., 
1999; Chugani, 2002).  Abnormal white matter and pyramidal cell growth are also 
apparent within the corpus callosum, left planum temporal, left inferior prefrontal gyrus, 
frontal lobe, hippocampus, medial nucleus septum, and mamillary body (Minshew et al., 
2005).  The frontal lobe demonstrates abnormal neural connectivity throughout the 






Neuroimaging Patterns in ASC 
Over 20 years ago, researchers speculated that autism is related to impaired neural 
connectivity resulting in functional deficits in cortical and subcortical information 
processing (Horwitz, 1988).  Only in recent years has research confirmed the neural 
connectivity hypothesis through measuring metabolic processes with positron emission 
tomography (PET) or single photon emission computed tomography (SPECT; Ohnishi et 
al., 2000) as well as cerebral blood flow (CBF) in real time using fMRI (Wicker et al., 
2008).  These approaches provide indications of abnormal glucose metabolism, 
hyperperfusion (i.e., excess blood flow), or hypoperfusion (i.e., diminished blood flow).  
Such research is critical for evaluating the phenotypes in ASC and for establishing the 
need to offer interventions associated with regulating these processes (Coben & Myers, 
2008).  
Extensive research has been conducted in exploring deficient CBF especially 
within and around the frontal lobe (Limsila et al., 2003; Ohnishi et al., 2000; Chandana et 
al., 2005).  ASC specifically has abnormal CBF within the medial prefrontal cortex, 
anterior cingulate gyrus, and right medial temporal lobe, which reflect deficits in TOM, 
obsessive behaviors, and need for sameness (Ohnishi et al., 2000).  Further, autism 
spectrum is differentiated by abnormal CBF in the bilateral insula, superior temporal gyri, 
and left prefrontal cortices suggestive of global cognitive impairments in language, 
executive functioning, and sensory integration. In a large sample (n = 117) of children 
with ASC, researchers found that these children had abnormal PET scans indicative of 





temporoparietal lobes associated with severity of language impairments (Chandana et al., 
2005).  Chandana et al. (2005) suggested that this results in the development of 
disorganized microcircuitry and more tightly packed columns impeding 
neurotransmission.     
There has been a growing body of neuroimaging research in autism using fMRI to 
evaluate the neuronal pathways for problems related to social-cognitive abilities like 
TOM (Baron-Cohen et al., 1999; Iacoboni & Dapretto, 2006; Koshino et al., 2005; 
Rinaldi, Perrodin, & Markram, 2008; Silk et al., 2006; Vollm et al., 2006; Welchew et al., 
2005).  fMRI imaging has explored the connectivity theory in people with ASC and it has 
been found that when presented with emotional expressions there is indication of 
abnormal functional connectivity in medial temporal lobe areas, specifically in the 
amygdala, hippocampus, and parahippocampal gyrus (Welchew et al., 2005).  Other 
fMRI research suggested that there is hypoconnectivity or lower synchronization amongst 
anterior regions and increased processing information in the right (Koshino et al., 2005).  
This right side processing is opposed to the primarily left side processing in normative 
controls (Koshino et al., 2005).  In the prefrontal cortex, hyper-connectivity has been 
found that may lead to deficits in higher order functioning such as with socialization, 
attentional deficits, and cognitive inflexibility or repetitive behaviors (Rinaldi et al., 
2008).  Adults with ASC utilize primarily linguistic and memory functions when 
processing nonverbal forms of communication rather than emotional centers in the brain 
such as the amygdala or left prefrontal region (Baron-Cohen et al., 1999).  Wicker et al. 
(2008) also explained that there was hypoconnectivity between the ventrolateral and 





attentional emotional processing as well as affective emotional expression.   
TOM and empathy are identified in areas of the medial prefrontal cortex, 
temporoparietal junction, and middle and inferior temporal gyri (Vollm et al., 2006).   
The same research has found differences between TOM and empathy where empathy 
activated the cingulate and amygdala and TOM activated the orbitofrontal cortex, middle 
frontal gyrus, cuneus, and superior temporal gyrus.  Empathy was linked to frontal lobe 
areas such as with Broca’s area or pars opercularis and bilateral dorsal and ventral 
premotor areas (Leslie, Johnson-Frey, & Grafton, 2003).  In another study on TOM, there 
was bilateral damage to the orbito-frontal cortex resulting in deficits in more complex 
TOM tasks like faux pas or mistakes in TOM, apparent particularly in high functioning 
ASC (Stone, Baron-Cohen, & Knight, 1998).  Further, individuals with unilateral damage 
did not show deficits with TOM tasks.  Lastly, sociopaths and ASC, although both 
sharing underlying problems in empathy, are distinguished in fMRI literature by the 
differences in processing TOM with sociopaths having no perceived deficit in 
orbitofrontal cortex and temporopareital cortices (Blair, 2008).  
In high functioning autism, the research on fMRI functional connectivity has 
found less activation in lateral and medial premotor cortex, dorsolateral prefrontal cortex, 
anterior cingulated gyrus, and caudate nucleus when undergoing mental rotation tasks, 
which is a result of problems in executive functioning and working memory (Silk et al., 
2006).  The caudate nucleus is the link to frontoparietal networks for attention, cognitive 
control, and visuospatial processing (Silk et al., 2006).   In another article, individuals 
with high functioning autism demonstrated hypoconnectivity in frontoparietal areas when 





occurrence of decreased size of the genu in the corpus callosum (Just et al., 2007).  
Adults with high functioning autism or Asperger syndrome compared to a normative 
sample were significantly different in processing of angry and happy faces compared to a 
normative sample in a recent study using a 3-T whole body imager, a type of fMRI 
(Wicker et al., 2008).  Wicker et al. (2008) showed a lack of activation in the dorsomedial 
prefrontal cortex and right ventrolateral prefrontal cortex in individuals with ASC.  Those 
areas are associated with comprehending social significance of emotional facial features.  
The medial prefrontal region is particularly an important integrator of information from 
cortical and subcortical systems like the amygdala, another deficient area of ASC 
(Wicker et al., 2008).  In addition, the occipital cortex showed little interaction in the 
fusiform gyrus, an area that is responsible for social/emotional perceptual networks 
(Wicker et al., 2008).   
One specific theory explaining the main deficit in autism has been the mirror 
neuron system, which influences social cognitive functioning in areas such as nonverbal 
and social communication (Iacoboni & Dapretto, 2006).  Iacoboni and Dapretto (2006) 
provided a thorough overview of the mirror neuron system and its relation to TOM.  They 
point to the interconnections between the superior temporal cortex, inferior parietal 
cortex, and inferior frontal cortex through white matter tracts alongside the arcuate 
fasciculus.  Frontal and parietal network, particularly the agranular frontal cortex, 
provides the basis for movement of body parts into actions (Iacoboni & Dapretto, 2006).  
Mirror neuron circuitry within the frontal regions is found at the inferior frontal gyrus and 
ventral premotor cortex, which are interconnected with the inferior parietal cortex.  The 





circuitry for imitation.  The frontal mirror neuron system is important for the “goal of the 
action” (p. 943).  The pars opercularis found within Broca’s area is the location of a large 
majority of the MNS activity, and suggests the evolutionary basis for language in 
imitation and social interconnectedness (Coben, 2009b; Iacoboni & Dapretto, 2006).  The 
pars opercularis is important for reflecting and predicting an observed model’s 
movement.  Connectivity with the temporal, parietal, and frontal networks is critical for 
imitative learning and social mirroring.  The MNS network, amygdala, and insula are 
critical for the complex sensorimotor processing especially when interpreting and 
understanding the intentions of others as well as the perception of self.  The neural 
substrates for TOM consist of fronto-temporal, supplementary motor, and bilateral 
temporal and parietal areas (Baron-Cohen et al., 1999).  There is also a subcortical 
involvement found in the left sides of the amygdala, hippocampal gyrus, and striatum as 
well as a bilateral involvement in the insula.  
Neurological Patterns in ASC 
Quantitative EEG (QEEG) is the statistical analysis of raw EEG data through 
comparison of the EEG spectrum (e.g., theta/beta ratios of 3:1 or greater indicative of 
ADHD) or comparative normative databases in order to identify standard deviations of 
brainwave activity (Demos, 2005; Thompson & Thompson, 2003; Townsend, 2007).  It 
may either be represented in the form of color-coded maps of the 10-20 sites or else in 
statistical quantitative data utilizing a measure such as z-scores or standard deviations for 
comparison with a normative EEG sample.  QEEG has been argued to be the most 
effective method of assessing brain function and differentiating autism with normative 





to suppress mu rhythms, connectivity irregularities, and elevated theta and delta waves 
(Coben, 2009b).  Also, QEEG has been used to differentiate ASC and control groups 
with up to 95.2% accuracy, and these differences were consistent over a 3-month period 
(Chan & Leung, 2006).   
The functional neuroimaging approaches previously noted are considered invasive 
procedures over QEEG because they require injections, consumption of radioisotopes, or 
exposure to radiation in order to assess brain function (Demos, 2005; Thompson & 
Thompson, 2003; Townsend, 2007).  In addition, although the use of fMRI is less 
invasive than SPECT or PET, the equipment is limited to high-tech research labs and can 
cost hundreds of thousands of dollars and even more if there is the use of higher field 
magnets which increase sensitivity (Wilkie, 2009). Also, the temporal resolution of fMRI 
is limited due to the problem that blood oxygenation changes within seconds whereas 
thought processes change within milliseconds (Wilkie, 2009).  QEEG is the least invasive 
measure for brain function, has the best temporal resolution, and is more readily available 
because of the affordability and portability of the equipment and software (Demos, 2005; 
Thompson & Thompson, 2003; Townsend, 2007).  In addition, the portability has special 
implications for outpatient clinical settings or remote rural areas far from hospitals or 
universities where access to technologically advanced equipment is limited. 
In an early case study on QEEG in ASC, the researchers found that an adult with 
autism was found to have higher amplitude brainwave activity in the right anterior area 
suggestive of behavioral symptoms associated with aprosodia of speech, impulsiveness, 
and difficulty with social behaviors (Harrison, Demarre, Shenal, & Everhart, 1997).  The 





theta, alpha, sensorimotor, and beta, as well as higher theta/beta ratios, and unstable 
absolute amplitude.  Another QEEG study found high delta and low alpha power, which 
was able to differentiate autism from a normative population (Chan, Sze, & Cheung, 
2007).   
In addition to abnormal EEG oscillations and localization, connectivity measures 
are driving much of the EEG research on autism providing a much more complex 
understanding of the condition (Coben, 2009a,b; Coben & Myers, 2008; Coben & Myers, 
2010; Coben & Padolsky, 2007; Minshew et al., 2005; Thatcher et al., 2008).  One 
thought is that neural hypoconnectivity is in part due to reduction in the corpus callosum, 
left planum temporal lobe, inferior prefrontal gyrus (Minshew et al., 2005).  Further, the 
corpus callosum may play a critical role in connectivity in individuals with ASC because 
of its physiological basis for connectivity in brain function (Coben & Myers, 2008; see 
also Coben, 2009b; Just et al., 2007).  In a study consisting of 54 children with ASC, 
researchers found significantly shorter phase shift duration particularly for alpha 1 (8-10 
Hz) and longer phase lock duration in alpha 2 (10-12 Hz) in the occipitoparietal regions 
(Thatcher et al., 2008).  The study reflected prior research that children with ASC have 
reduced thalamo-cortical connections attributed to GABA inhibitory deficiencies.  Coben 
and Myers (2008) presented cases and summarized research suggesting that ASC consists 
generally of hyperconnectivity in frontotemporal and left hemisphere intrahemispheric 
regions and hypoconnectivity in orbitofrontal, right posterior, frontal-posterior, and left 
hemispheric regions.  These areas represent executive functioning, social reasoning, 
emotional recognition, social pragmatics, and informational processing.  Coben and 





rather than simply basing the diagnosis on subjective reports or observations.   
Researchers summarizing EEG phenotypes in individuals with ASC have been 
complex, with issues like a lack of interhemispheric communication (Thompson & 
Thompson, 2003) and epileptiform activity particularly in temporal regions (Hughes & 
Roy, 1999; Minshew et al., 2005).  Children with ASC were identified as having high 
rates of at least 32% of EEG recordings showing epileptiform activity (Akshoomoff, 
Farid, Courchesne, & Haas, 2007), and in a review of EEG subclinical epileptic activity 
(i.e., no behavioral observations of seizures) in individuals with autism, studies showed a 
high occurrence of seizures from 20-30% on average and epileptiform activity ranging 
from 10.3% to as high as 72.4% (Kagan-Kushnir, Roberts, & Snead, 2005).  Kagan-
Kushnir et al. (2005) suggested a definite neurological basis for treating ASC through 
neurofeedback in addressing EEG abnormalities such as epileptiform activity. 
Other researchers have found EEG patterns for anterior sites that are asymmetric 
in children with high functioning autism (Sutton et al., 2005).  Specifically, those with 
right frontal asymmetry were more socially aloof and less capable of managing social 
interaction, but the intent and motivation was considered more active.  On the other hand, 
children with greater left midfrontal activity had higher social anxiety and more 
withdrawn due in part to anxiety (Sutton et al., 2005).  Sutton et al. (2005) explained that 
this is in contrast to other research that suggests right hemispheric asymmetry, rather than 
left, is more suggestive of anxiety.  Specifically, these EEG patterns may suggest the 
need to address frontal lobe asymmetry in order to accommodate for anxiety and social 
motivation issues common in ASC.  One example of this has been an intervention study 





ASC (Pineda et al., 2008). 
Another area that has been gaining attention in ASC is that of the mirror neuron 
system (MNS), which requires functional connectivity between left and right 
hemispheres (Iacobini & Dapretto, 2006).  The MNS is important in imitating and 
performing social interactions in the frontal and parietal regions of the cortex. The 
inferior frontal cortex and connections to the superior temporal sulcus through the arcuate 
fasciculus is the connectivity of the mirror neuron system and considered the network 
important for social imitation (Aziz-Zadeh, Koski, Zaidel, Mazziotta, & Iacoboni, 2006). 
The F5 site, left frontal lobe, shows a unique Mu wave activity which is thought to be 
consistent with ASC mirror neuron system, which impacts imitation of observed 
behaviors and emotional affect (Coben, 2009b), but other researchers have found C4 as 
being linked with mu rhythm (Oberman et al., 2005).  Bernier, Dawson, Webb, and 
Murias (2007) found that adults (n = 15) with high functioning ASC had reduced 
attenuation of Mu rhythms when observing movement, indicative of problems in 
imitation abilities. The mu rhythms are a sensorimotor processing function of 
frontoparietal networks suggestive of mirror neurons, which are suppressed during self or 
observed movements, and mu suppression has been found in individuals with ASC to be 
typically present only in self movement and not in observed movements, indicating that 
there is a disconnect between the mirror neuron and sensorimotor systems (Coben, 
2009b; Oberman et al., 2005; Pineda, 2005).  Mu suppression in children with ASC has 
been found to be improved through 15 hours of neurofeedback (Pineda et al., 2008). 
Other case reports identified individuals with ASC as consisting of high slower wave 





Mirror Neuron System (Thompson & Thompson, 2003).   
Prevalence and Costs 
Prevalence rates have been looked at closely in ASC, as opposed to observing 
simply incident rates, since ASC is considered a long-term disorder that is better assessed 
in specific time points and places (CDC, 2007, 2009).  Initially, the prevalence for ASC 
was rare, with approximately .4 to .5 per 1000 children identified in 1985 (CDC, 2007).  
From 1991 to 1999, the CDC (2007) identified a 500% increase in the prevalence rates of 
ASC.  To address the problem of varying and questionable survey methods, the CDC 
(2007) established stringent methodological criteria over a broad multisite review of 
ASC, and the CDC developed the Autism and Developmental Disabilities Monitoring 
(ADDM) Network to oversee the consistency of diagnostic formulation and reporting of 
prevalence amongst 8 year old children.  The ADDM data concluded in 2002 that 1 in 
152 children are diagnosed with ASC.  From 2002 to 2006, they continued this evaluation 
across 11 of the 14 ADDM sites areas in the United States finding 2,757 of 307,790 or 1 
in 110 children diagnosed with ASC, which represents an average increase of 57% since 
2002 (CDC, 2009).  These results also varied from site to site, with New Jersey having 
the highest prevalence rate of 1 in 100 children being diagnosed with ASC.  Furthermore, 
there was a 60% increase in boys and a 48% increase in girls with a male to female ratio 
of 4.5:1.  The cause for the increase has been debated in research and has not come to a 
specific cause (CDC, 2009).  One rationale has been that the label PDD from the DSM 
has allowed for a wide opening of variants of autism, which have led to this increase 
(Volkmar & Klin, 2005).  Higher functioning forms of autism like Asperger’s syndrome 





many children that had milder symptoms of autism and high educational performance 
were not identified as having autism.    
The cost of treating ASC has been estimated at around $35 billion per year 
nationwide to cover expensive interventions and educational needs (Ganz, 2006).  For 
each individual diagnosed with ASC, this represents approximately $3.2 million in costs 
over the course their lifetime including $29,000 per year for medical treatments 
associated with comorbid medical conditions, behavioral therapy, and medication (Ganz, 
2006). Medical costs alone range from $4,110 to $6,200 per year (Shimabukuro, Grosse, 
& Rice, 2008).   These costs can rise to $43,000 per year when including severe forms of 
ASC and expenses associated with special education and child care (Ganz, 2006).   
Despite these high rates of expenditures in providing assessment and interventions for 
ASC, Ganz (2006) showed a disparity in ASC funding of $100 million per year compared 
to other developmental disabilities such as cognitive impairments where government 
spends close to $51 billion.   
Autism in Older Adolescence and Adulthood 
The majority of research on ASC intervention research has been conducted 
primarily in infancy to early childhood with minimal research in adolescent, adulthood, 
and elderly populations (Coben et al., 2010; Roy et al., 2009; Wolf & Paterson, 2010).  
Because it is a neurodevelopmental disorder according to the APA, individuals with ASC 
continue to have problems beyond early childhood and fall further behind peers with 
limited access to gainful employment and specific work abilities that restrict them (Shea 
& Masibov, 2005).  Further, autism is a life-long condition that continues into adulthood 





neurological deficits compared to adults without ASC in processing of social-
communication (Baron-Cohen et al., 1999). Many adults with ASC will need supported 
housing or live within group home settings, separated from mainstream society despite 
the fact that some of these individuals demonstrate average to above average intellectual 
abilities (Shea & Masibov, 2005).  Individuals with ASC are often unable to maintain 
gainful employment or stable relationships and adults with this diagnosis are more likely 
to be victimized due to their social cognitive deficits (Shea & Masibov, 2005).  Despite 
all these challenges, research for adults with ASC is minimal, especially in regard to 
empirically supported interventions that may offset ongoing support services throughout 
a lifetime (Wolf & Paterson, 2010).  Nevertheless, there are researchers beginning to 
explore areas for interventions in adulthood particularly in employment (Howlin, Alcock, 
& Burkin, 2005).   
Neurofeedback Background 
Overview of Electroencephalography 
Neurofeedback begins with understanding the utility of electroencephalography in 
measuring and changing brain function.  Berger (1929) conducted the first human EEG 
and was the first researcher to analyze the raw EEG through a statistical procedure called 
fourier transform, the origin of quantifying EEG (i.e., QEEG) through mathematical 
analyses (for history, see Thatcher & Lubar, 2008).  Electroencephalography neurology 
has been widely beneficial across assessments and interventions in neurological 
conditions (e.g., Demos, 2005; Hughes & Roy, 1999; Rowan & Tolunsky, 2003; 
Thompson & Thompson, 2003).  A review of literature has found that the EEG has 





flow (Gunkelman & Johnstone, 2005).  Although EEG measurement occurs from the 
surface of the outer cortex, frequency bandwidths of the EEG spectrum also are 
indicative of subcortical electrical activity (Hughes & Roy, 1999).  Specifically, alpha 
rhythm is associated to pacemaker neurons projected from the thalamus, theta is 
produced primarily from GABA release within the nucleus reticularis, delta waves 
correlate with oscillator neurons within the thalamus, and beta waves are produced from 
cortical as well as thalamocortical electrical activity during higher information processing 
(Hughes & Roy, 1999).   
The 10-20 International System of Electrode Placement is the standard of EEG 
sensor placements identified through skull landmarks (e.g., nasion and inion) for initial 
measurements and determining 19 sites through 10% and 20% of the total measurement 
across the sagittal, coronal, and horizontal planes (Demos, 2005; Hughes & John, 1999; 
Jasper, 1958; Rowan & Tolunsky, 2003; Thompson & Thompson, 2003). The placements 
consist of each region of the cerebral cortex including the frontal (F sites), sensorimotor 
(C sites), temporal (T sites), parietal (P sites), and occipital (O sites) cortices.  Even 
numbers are associated with right hemisphere locations, odd numbers are associated with 
left hemisphere locations, and z is the zero line associated with the central split between 
left and right hemispheres.  Figure 1 below provides the EEG site locators: the 10-20 






Figure 1. The 10-20 System (permission by Wikipedia, 2010). 
Sensor sites record brainwave frequencies measured by hertz (Hz), cycles per 
second, and amplitude in microvolts ( V), height of the wave (Demos, 2005; Rowan & 
Tolunsky, 2003; Thompson & Thompson, 2003; Townsend, 2007).  Active sensors 
measure the sites noted above, and in addition to active sensors, there are reference 
placements that help to cancel common extraneous electrical noise like 
electromyography.  For the purpose of this paper, bandwidth frequencies in Dynamic 
Link Library (DLL) database consists of: Delta = 1-4 Hz, Theta = 4-8 Hz, Alpha = 8-12 





= 15-18 Hz, Beta 3 = 18-25 Hz, Gamma 1= 30-35 Hz, Gamma 2 = 35-40 Hz, and 
Gamma 3 40-50 Hz (Collura, Thatcher, Smith, Lambos, & Stark, 2009).  However, it 
should be noted that depending on the database for EEG software frequency bandwidths 
will vary (Demos, 2005; Thompson & Thompson, 2003; Townsend, 2007).   
Presently, EEG acquisition is the least invasive and least costly compared to all 
other current assessments of temporal brain function (Demos, 2005; Gunkleman & 
Johnstone, 2005; Thompson & Thompson, 2003; Wilkie, 2009).  PET and fMRI scans 
are typically only available in larger hospitals and university centers.  On the other hand, 
EEG is more readily available due to a broad range of practitioners due to the 
affordability and decreased exposure to neurochemicals and radiation.  In addition, it has 
the best temporal resolution of all the neurological assessments with relay of information 
within milliseconds (Demos, 2005; Gunkleman & Johnstone, 2005; Thompson & 
Thompson, 2003). 
See Appendix A for information on each frequency wave bandwidth, description 
of cognitive states, function, morphology, and disorders associated with each wavelength 
(Demos, 2005; Thompson & Thompson, 2003; Townsend, 2007; Wikipedia, 2005).  
Theoretical Background for Neurofeedback 
Neurofeedback is essentially EEG biofeedback, and allows individuals to learn to 
modify brainwave activity to alter and improve states of cognitive processes such as 
alertness, attention, calmness, internal focus, or flexibility (Demos, 2005; Thompson & 
Thompson, 2003).  The theoretical basis for neurofeedback comes from the Law of Effect 
and learning theories that propose that rewarding a specific behavior will increase the 





Law of Effect, learning theories such as operant conditioning have found that successive 
approximations toward a desired behaviour through positive reinforcement will increase 
the likelihood of the behaviour reoccurring (Skinner, 1935, 1937, 1948, 1950).  
Conditioning is the influence of changing the direction of behavior through a reinforcing 
stimulus that is temporally related with the order of stimulus and reward strengthened 
through correlation or contingency (Skinner, 1950).  The operant conditioning paradigm 
set the implications that contingent reinforcement is the most basic form of behavior even 
before classical conditioning (Skinner, 1935).  Initially, the process of neurofeedback 
presents much like the incidental learning of pigeons trained with superstitious behaviors 
(Skinner, 1948), and conditioning maybe completed through complex operant behaviors 
that result in reinforcement through successive approximation (Skinner, 1937).   
Neurofeedback may involve other learning approaches, such as classical 
conditioning that influence the improvement of brain function.  Thompson and 
Thompson (2003) suggest that through neurofeedback the desired brain state becomes a 
conditioned response over time in completing homework assignments.  However, 
neurofeedback is based primarily on operant conditioning through auditory and/or visual 
rewards that result when EEG frequencies reach specified amplitude thresholds (Demos, 
2005; Thompson & Thompson, 2003; Townsend, 2007).  The temporal relationship 
between EEG patterns and auditory/visual rewards successively approximates the brain 
behavior toward increased performance.  The individual who participates in training 
becomes increasingly self-aware of what brain behaviors are expected and is also able to 
generalize this learning to real-life situations such as in school or work (Demos, 2005; 





or training technique that helps individuals to learn to modify neural activity in order to 
balance arousal levels and self-awareness of various cognitive states (Demos, 2005; 
Thompson & Thompson, 2003).  There are disorders like ADHD that have specific EEG 
phenotypes identified as having theta/beta ratios greater than 3:1 in frontocentral regions 
associated with inattention and poor concentration, and suggest the need to inhibit slow 
wave frequencies while increasing sensorimotor and Beta 1 (Demos, 2005; Thompson & 
Thompson, 2003).   
There was a need to provide a formal definition of neurofeedback in order to 
express to the general public and other professionals what neurofeedback is and how it 
works.  The International Society for Neurofeedback and Research (ISNR) (2009) 
provided this definition for consistency in the literature and research on neurofeedback:  
Like other forms of biofeedback, neurofeedback training (NFT) uses monitoring 
devices to provide moment-to-moment information to an individual on the state of 
their physiological functioning. The characteristic that distinguishes NFT from 
other biofeedback is a focus on the central nervous system and the brain.  NFT 
has its foundations in basic and applied neuroscience as well as a data-based 
clinical practice.  It takes into account behavioral, cognitive, and subjective 
aspects as well as brain activity.  NFT is preceded by an objective assessment of 
brain activity and psychological status. During training, sensors are placed on the 
scalp and then connected to sensitive electronics and computer software that 
detect, amplify, and record specific brain activity.  Resulting information is fed 
back to the trainee virtually instantaneously with the conceptual understanding 





activity is within the designated range.  Based on this feedback, various principles 
of learning, and practitioner guidance, changes in the brain patterns occur and are 
associated with positive changes in physical, emotional, and cognitive states.  
Often the trainee is not consciously aware of the mechanisms by which such 
changes are accomplished although people routinely acquire a ‘felt sense’ of these 
positive changes and often are able to access these states outside the feedback 
session. (para. 1-2) 
Neuroplasticity and Neurofeedback 
 The neuroscientists Ernesto Lugaro in 1909 and Jean Demoor in 1896 were the 
first to explore the central nervous system as being plastic and the ability to regenerate 
and grow new neuropathways (Jones, 2004).  Neuroplasticity has been developed in 
neurotransmission for excitatory and inhibitory pathways such as with GABA and 
flutamate (Gynther, Calford, & Sah, 1998).  Cognitive retraining, pharmacotherapy, 
stimulating environments, and other approaches may actually regenerate and promote 
growth in neuronal connectivity through increasing dendrites and creating larger synapses 
(Beauregard & Lévesque, 2006; Jones, 2004; Malkowicz & Martinez, 2009; Pinel, 2008).  
Further, neuroplasticity proves that adulthood is not the end to the development of 
neuropathways; rather it is a lifelong process (Jones, 2004).  It is particularly important 
for adults with ASC who tend to have less brain weight and abnormal brain circuitry that 
develops well into adulthood (Minshew et al., 2005).   
Kaiser (2008) identified that connectivity patterns increased from ages five to 35 
coinciding with increased anterior myelination in the brain in normally developing adults.  





neurodevelopmental disorders to improve their level of functioning through 
neurofeedback.  Malkowicz and Martinez (2009) explained that modifying the 
thalamocortical oscillatory EEG activity is an indication of neuroplasticity.  Malkowicz 
and Martinez explain that the process of neurofeedback results in changes of EEG 
activity which is related with functional aspects of the brain such as neuromodulation of 
neurotransmitters, metabolic activity, and other processes related to structural changes as 
well.   
Lévesque, Beauregard, and Mensour (2006) conducted one of the only studies to 
look at the effects of neurofeedback through fMRI.  The researchers found significant 
changes in children with ADHD after neurofeedback sensorimotor rhythm (SMR) 
training with significant increases in metabolic activity in the striatum. Furthermore, 
there are long-term effects of neurofeedback in children with ASC on improving 
behaviors and neuropsychological functioning, which is suggestive of structural long-
term changes as opposed to short-term treatment effects (Kouijzer et al., 2009a; Coben, 
2009a).  It would logically follow that research in neurofeedback during adulthood is 
necessary to explore efficacy in improving neurocognitive functioning, because it may be 
another opportunity to improve and promote neuroplasticity especially in adults with 
ASC.   
Brief History of Neurofeedback 
The history of neurofeedback has several major ground breaking research studies 
that built upon each other identifying that brain behavior can be modified based on the 
operant learning approaches.  In 1963, Joseph Kamiya opened the door to neurofeedback 





training, which was not thought to be possible (Demos, 2005; Thompson & Thompson, 
2003; Townsend, 2007).  However, by 1968 at the University of California Los Angeles, 
Maurice Barry Sterman went further than merely controlling brainwave patterns through 
the application of neurofeedback in the medical arena.  He developed the concept of 
sensorimotor rhythm or SMR, which is the frequency of 12-15 Hertz.  Through operant 
conditioning, he trained 10 cats to increase SMR activity.  He was later asked by NASA 
to study the exposure of hydrazine or rocket fuel.  For the experiment, he gathered 50 cats 
including the 10 SMR trained cats, and all 40 of the cats that were not trained in SMR 
had seizures, while the remaining 10 were seizure resistant.  He later provided operant 
conditioning to increase SMR in human patients with epilepsy and found that it decreased 
the frequency, severity, and duration of seizures.  Sterman, without foresight, had 
inadvertently stumbled on the remarkable benefits of neurofeedback (Demos, 2005; 
Thompson & Thompson, 2003). 
Neurofeedback was more thoroughly explored in the 1960s and 70s when it was 
identified that individuals could both control specific frequencies and identify mental 
states associated with the frequencies (Hammond, 2006).  Beta has been identified as an 
outward focus, attention, and concentration; alpha is seen as a state of relaxation, idling, 
and disengaged; theta is viewed as a day-dream state and inefficient mental processes; 
and delta are typically experienced in sleep. Through the use of computer technology, an 
individual is able to view the changes in brainwave activity during different states of 
mind and identify ways to manipulate them through coaching and practice improving 
cognitive efficiencies, flexibility, resting, awareness, and control (Hammond, 2006).  In 





10 to 60 sessions (Hammond, 2006).  The brain consists of short and long-range 
connections throughout subcortical structures, primarily the thalamus, and across a 
number of cortical centers, synchronization of pyramidal cells (Collura, 2008).  
Normalizing EEG power and connectivity is considered the most validated approach in 
neurofeedback to date (Collura, 2008).  The connectivity measures associated with LZT 
training and considered the most frequently used are phase, coherence, and asymmetry 
(Collura, 2008).  
Efficacy of Neurofeedback in Autism Spectrum Condition 
Case Study Research 
There have been a number of researchers who have explored neurofeedback as a 
viable intervention for ASC through case study research (e.g., Beaumont & Montgomery, 
2005; Coben & McKeon, 2009; Collura et al.,, 2010; Cowan & Markham, 1994; Othmer, 
2007; Rutter, 2009; Sichel, Fehmi, & Goldstein, 1995; Thompson & Thompson, 2003a, 
b; Thompson et al., 2010b).  The first publications on neurofeedback efficacy for treating 
ASC was by Cowan and Markham (1994) regarding an 8-year-old girl with high 
functioning autism.  They found elevated alpha-theta wave amplitudes in the parietal and 
occipital lobes, and set up training with a bipolar montage inhibiting theta-alpha (4-10 
Hz) ratios and rewarding beta (16-20 Hz).  The girl showed observed improvements in 
autistic behaviors, increased attention, and improved social and academic functioning.  
Many other clinicians have reported protocols similar to Cowan and Markham’s such as 
Beaumont and Montgomery (2005) with a 7-year-old with ASC in inhibiting theta (2-8 
Hz) and rewarding beta (16-20 Hz).  They conducted 33 sessions and identified gains 





noted improved parental reports according to the Childhood Autism Rating Scale, Autism 
Behavior Checklist, and Vineland Adaptive Behavior Scales.   
Other neurofeedback investigators such as Thompson and Thompson (1995, 
2003a, 2003b), Linden (2004), and Othmer (2007) have reported case studies indicating 
that neurofeedback is effective improving attention, behavioral problems, socialization, 
sleep, obsessive symptoms, speech, and sensory integration for individuals with ASC.  At 
the Annual Meeting of the Association for Applied Psychophysiology and Biofeedback, 
Thompson and Thompson (2003a) presented 60 case reviews of individuals with ASC 
with training in frontal and parietal sites especially right hemispheric training for 
individuals with high functioning ASC.  Thompson and Thompson (2003b) presented 
case details of four children and adults diagnosed with ASC receiving 40-100 sessions 
with improved neuropsychological functioning.  One of the cases was a 13 year-old boy 
with ASC who received training on the sensorimotor cortex (i.e., C2 and C4) with 
rewarding 13-15 Hz and inhibiting 3-10 Hz.  The authors reported that the child 
improved in emotional regulation, decreased anxiety and impulsivity, and improved 
educational performance with sustained results in an eight year follow up.  Othmer 
(2007) presented positive results in case study research with neurofeedback in children 
who have ASC that led to decreased need for special education services and autistic 
symptoms through training SMR and calming overall arousal in the right hemisphere and 
frontotemporal lobes for stabilizing epileptiform activity and social cognition (e.g., P4, 
T3, T4, Fp1, F2).  The sessions ranged from 28 to close to 100 sessions of 20-30 minute 
training.   





autism who showed observed improvement in behaviors and movement toward 
normalization of brain function (Sichel et al., 1995).  Utilizing 19-site QEEG measures, 
they found theta to beta ratios greater than three similar to profiles of ADHD, and 
focused on reducing theta and rewarding SMR along the sensorimotor strip and parietal 
lobe with reference to ears.  After 31 sessions, the boy had observed improvement for 
social behaviors, improved sleep, a reduction in self-stimulation, and an increase in 
appropriate eye contact.  QEEG results found decreased power ratios across 15 sites.  
Sichel, Fehmi, and Goldstein helped to set the stage for conducting meaningful research 
and submitting it to the still developing Journal of Neurotherapy, which has provided a 
venue to report research on the efficacy of neurofeedback. 
Recently, Coben and McKeon (2009) released a single-subject case report of a 
young boy who had 165 epileptiform paroxysmal discharges, and reported specifically on 
utilizing QEEG-guided neurofeedback.  The protocol consisted of temporal-occipital sites 
(i.e., O1 and T3) using 2-channel coherence training, rewarding 1-7 Hz and inhibiting 1-4 
HZ and 8-13 Hz.  Coben and McKeon found that this improved neuronal regulation 
across regions as opposed to just the focal epileptiform activity.  They also found 
significant improvement on the Autism Treatment Evaluation Checklist (ATEC) showing 
an 82% overall improvement after one year of training. In another study addressing the 
neurological problems associated with ASC, Coben and Hudspeth (2006) explored NFT 
in mu rhythms (i.e., suggestive of mirror neurons and social interactions). They found a 
significant reduction in mu activity and increased social functioning for 14 children with 
ASC.  





on hemoencephalography (HEG) neurofeedback (Berman, Sudol, Miller, & Berman, 
2005; Coben, 2006; Limsila et al., 2004).  Hemoencephalography measures blood flow 
dynamics and cellular metabolism, and because of this, HEG neurofeedback provides the 
functional capability to have direct control over the prefrontal lobe’s cerebrovascular 
system, a critical site for conditions like ADHD, depression, and migraines (Carmen, 
2001).  Further, the use of HEG neurofeedback has the benefit of minimizing artifacts 
and is less invasive procedurally when compared to EEG neurofeedback (Carmen, 2001).  
The largest HEG neurofeedback case series was conducted by Limsila et al. (2004) with 
180 children who were diagnosed with ASC.  They found that there was improvement 
after 40 sessions of prefrontal HEG training as indicated by improvement in average 
values of blood oxygenation, grade point averages, and positive reports by parent, 
teacher, therapist, and psychiatrist reports.  Berman, Sudol, Miller, and Berman (2005) 
found similar results with a child age 14 at a charter school that gained five points in 
nonverbal intelligence, increased 22 points for Stroop testing, and improved hand writing 
legibility.  The authors reported that five out of the six original participants for HEG 
training were unable to complete pre or post testing data, so they were excluded from the 
study.  Finally, Coben (2006) presented the most comprehensive research on HEG in 
ASC with 28 children who received either near infrared or passive infrared HEG for 20 
sessions.  Compared to a wait-list control of 12 children, there were statistically 
significant reduction of autistic symptoms as measured by the ATEC and other 
behavioral rating scales, improved neuropsychological performance with executive 
functions, language, visuospatial, and attention indices, increased temperature based on 





Coben reported that there were no differences between the two types of HEG.  There 
have been no peer-reviewed articles in this area of neurofeedback for children or adults 
with ASC, and these three studies have had limitations relative to past treatment, drop-out 
rates, and limited reports on specific methodology and statistical analyses.   
Thompson et al. (2010b) provided a comprehensive overview of 159 clients with 
Asperger’s syndrome or autistic disorder over a 15-year period.  This may have included 
the previous mentioned case studies in other research (Thompson & Thompson, 2003b).   
They evaluated the efficacy of neurofeedback in combination with metacognitive training 
and respiration, electrodermal, and heart rate variability biofeedback.  The sessions 
ranged from 40-60 sessions and a majority of training consisted of decreasing slow wave 
activity (3-7 Hz) and beta spindling (23-35 Hz), and increasing SMR (12-15 or 13-15 
Hz).  They primarily used central and frontocentral sites for training.  The authors found 
significant improvements for psychological assessments that included questionnaires that 
assessed the core symptoms of Asperger’s syndrome, Conners’ Global Index, DSM-IV 
criteria for ADHD, and psychological testing like TOVA and IVA, achievement, and 
intelligence testing.  Interestingly they found an average Full Scale IQ score gain of nine 
points.  Thompson et al. further found a significant improvement in EEG ratios.  
Overall, qualitative case studies are problematic because they do not generalize 
well and create standards for practice.  One confounding variable could disrupt the entire 
study or lead to type I or type II errors.  For example, Beaumont and Montgomery 
(2005), in their case study, reported the confounding variable of neurostimulant 
medication being added during the neurofeedback intervention, making a type I error 





diaphragmatic breathing and metacognitive strategies in addition to neurofeedback in 
many training sessions, and this confounds their findings.  Case studies in neurofeedback 
has lacked sound methodology with vague reports of pre and post measure findings, 
retrospective rather than prospective collection, tendency for researcher biases, and not 
establishing a stable baseline of functioning (e.g., one pretest measurement as opposed to 
more than one).  Single-case research would improve methodology over qualitative case 
studies because it offers time-series measurement, quantitative data collection, 
experimental control within the individual, and use of statistical and/or visual inspection 
analyses of the hypotheses (Blampied, Barabasz, & Barabasz, 1996).  Neurofeedback 
may also be better evaluated through single-case research because it provides in-depth 
detail of the impact of the intervention, conditions like autism in the DSM-IV vary so 
greatly in symptoms that it would be dismissed to assume a sample of individuals with 
ASC will be equivalent, and regardless, each case becomes in and of itself an individual 
research study with a control (i.e., baseline) and experimental condition (Blampied et al., 
1996).   
Quasi-experimental Research Studies 
Neurofeedback has advanced as an effective tool in treating ASC in the last 
decade with quasi-experimental research, initially explored in pilot studies to evaluate 
both the intervention as well as testing tools to evaluate its efficacy (Jarusiewicz, 2002; 
Knezevic et al., 2009, 2010; Scolnick, 2005).  Jarusiewicz (2002) and Scolnick (2005) 
explored the efficacy of neurofeedback in children with ASC, setting the need for further 
exploration of efficacy by other researchers (Coben & Padolsky, 2007; Kouijzer et al., 





a nonrandomized experimental-control matched control group of 24 participants.  With 
an average of 36 sessions at 30 minutes per session, the study found efficacy in utilizing 
symptom-based protocols which consisted of sensorimotor, frontal, and temporal sites to 
improve socialization, arousal, emotional stability, and expressive communication.  The 
protocol also consisted of inhibiting 2-7 Hz and 22-30 Hz because of high amplitudes for 
slower and faster bandwidths.  Results included statistically significant improvement (p < 
.001) in parent-ratings on the ATEC for the ASC group compared to the control group, 
specifically in speech/language communication, sociability, sensory/cognitive awareness, 
and health categories.  In the second pilot study, Scolnick (2005) conducted a less 
stringent single group study with a high recidivism rate of five youth with ASC out of an 
initial group size of 10 dropping out before completing 12 sessions, and did not achieve 
statistically significant results in pre and posttest QEEG.  However, the researcher noted 
that the QEEG of the five students who completed 24 sessions appeared to normalize, 
and parents and teachers reported that the children had improved in behaviors.  Despite 
the findings of limited efficacy, this was the first peer-reviewed article outside of a 
biofeedback specific journal such as the Journal of Neurotherapy or Applied 
Psychophysiology and Biofeedback Journal. 
Later, Knezevic, Thompson, and Thompson (2009, 2010) conducted a 
neurofeedback pilot study with 19 participants ages 7 to 21 years who were diagnosed 
with Asperger’s syndrome to evaluate the utility of the Tower of London-Drexel 
(TOLDX) in assessing the efficacy of neurofeedback.  They conducted the single channel 
Cz EEG measure ToLDX for pre and post measures after 40 sessions of neurofeedback 





computer game software, the participants were asked to be attentive to the feedback in 
the form of points and to use their own method or approach to remain alert.  With three to 
four-minute training intervals and approximately 40 minutes each session, clients were 
rewarded at Cz for SMR (13-15 Hz) and/or problem solving (15-18 Hz) and for inhibiting 
slower frequency bandwidths (e.g., 4-8 Hz, or 3-10 Hz).  They found statistically 
significant improvement in a paired samples t-tests for pre and post measures of 
executive functioning, the ToLDX.  However, the study established a set protocol that 
required 40 to 60 sessions of neurofeedback, and in addition to another intervention, 
metacognitive training, which is a significant confounding variable in terms of 
methodology and efficacy of neurofeedback as a treatment alone.  Nevertheless, 
Knezevic, Thompson, and Thompson included adult participants with ASC, which has 
helped to explore possible efficacy of neurofeedback in adults. 
In another nonrandomized control group study, neurofeedback improved QEEG 
normalization, executive functioning, and parents’ observations in seven children with 
ASC ages 8 to 12 through inhibiting theta and rewarding beta over 40 sessions during a 
three-month period (Kouijzer et al., 2009b).  The sessions were conducted with 3 minutes 
baseline, 3 minutes feedback, and one-minute rest intervals.  The multiple outcome 
measures included the Children’s Communication Checklist, AUT-R, theta/beta ratios in 
QEEG, and neurocognitive testing such as the stroop and symbol digit coding tests.  The 
authors found statistically significant changes on post-test measures via a MANOVA (as 
high as p < .001) among ASC compared to the control group.  The researchers suggest 
that these findings are indicative of improved flexibility in the anterior cingulate cortex 





pattern found in DMN for ASC appears to be the lack of deactivation in ACC, so 
Kouijzer, et al. (2009b) assumes that the reduction of theta activity may improve network 
flexibility to perform better on attention control tasks such as the stroop and symbol digit 
coding.  The two main limitations to this study are the small sample size and that the 
protocol was not individualized (i.e., neurofeedback training based on QEEG). 
The most comprehensive and well-formulated quasi-experimental research to date 
was conducted by Coben and Padolsky (2007) with the largest sample size of 37 children 
with ASC ages 4 to 14 for the experimental condition, and 12 matched controls placed on 
a wait list.  The experimental condition consisted of 20 sessions of QEEG-guided 
neurofeedback protocols conducted three times per week.  Treatment efficacy was 
measured by comprehensive pre and post measures consisting of the ATEC, Gilliam 
Asperger Disorder Scale (GADS), Gilliam Autism Rating Scale (GARS), Behavior 
Rating Inventory of Executive Function (BRIEF), Personality Inventory for Children 
(PIC-2), baseline measures of neuropsychological functioning, QEEG, and Infrared (IR) 
Imaging.  The researchers provided individualized neurofeedback protocols for each 
participant using bipolar montages.  The analysis of QEEG identified hyperconnectivity 
for frontal-temporal sites.  For one participant, the researchers rewarded alpha frequency 
and inhibited low and higher bandwidths at F8 and F7 to reduce hyperconnectivity with a 
majority of training being in F8-F7, Ft8-Ft7, T4-T3.  Results of the experimental 
condition consisted of statistically significant results (p < .01) with 76% decrease in 
hyperconnectivity patterns, improvement in language functions, regulation of thermal 
activity according to the IR imaging, and 40% reduction in core symptoms of ASC 





measured from subjective reports to testing to neurophysiology.  There were no reports of 
symptoms worsening.  The authors analyzed the benefit to harm ratio as determined by 
parents as being 89:1 which surpassed all current therapies or treatment for ASC (e.g., 
behavioral, chelation, risperidone).  
Experimental Research Study 
There has been only one neurofeedback article reporting on treatment of 
individuals with ASC that consisted of an experimental research design, and the report 
included both the initial pilot study and the actual follow-up study (Pineda et al., 2008).  
The pilot consisted of a single-blind randomized controlled trial (RCT) with an 
experimental and placebo condition (both n = 8) of boys with high functioning ASC who 
had an IQ > 80 ages 7-17, and the follow-up study consisted of a double-blind RCT with 
males and females (ages 7-17) and a larger sample size (n = 10 in the placebo group; n = 
9 in the treatment group; Pineda et al., 2008).  The neurofeedback providers were not 
aware of whether the participants were provided feedback or placebo because they were 
preset prior to the sessions by separate clinicians.  Pre and post measures consisted of 
QEEG using Mini-Q software by Brainmaster, Mu Suppression Index (i.e., assessing the 
changes in mu power in response to observation of movement), and Test of Variables of 
Attention (TOVA).   
In the placebo condition, the participants received an artificially generated mu 
rhythm and trapezius electromyography (EMG) or muscle activity to allow control over 
EMG artifacts, thus allowing placebo participants to believe that they were receiving 
EEG feedback when they were really receiving EMG feedback.  For the experimental 





30-minute sessions three times a week for 10 weeks.  Neurofeedback consisted of site C4 
with feedback for mu rhythm (Oberman et al., 2005 for reduced mu power in ASC), and 
inhibiting trapezius EMG activity (30-60 Hz).  The feedback for both conditions 
consisted of computer games with two feedback bars indicating EEG and EMG activity.  
The experimental group would proceed in the game when the conditions were met for 
reaching 8-13 Hz at C4 and 30-60 Hz at the trapezius muscle, while the placebo would 
only receive feedback from the EMG activity.  Along with this feedback, experimenters 
provided verbal reinforcement by praising participants for paying attention and 
proceeding through the games.   
Pineda et al. (2008) used repeated measures ANOVA within and between for 
QEEG, Apraxia Imitation Scale, ATEC, and mu power, and they used a paired-sample t-
test (two-tailed) for TOVA.  For the pilot study, they found a significant difference (p < 
.05) in the experimental group compared to control group with changes in decreased 
amplitude coherence and differences in mu and delta frequency bands, where as the 
placebo condition showed increases in coherence.  The larger scale study found similar 
significant findings (p < .01 to .05) for QEEG measures.  For the TOVA, there was a 
significant difference found in the pilot and larger scale study (p < .02 for both 
comparisons) for overall ADHD score and errors of commission with improvement of up 
to 70% on their TOVA scores in the experimental group.  There were significant 
differences between the experimental and placebo group for both the pilot and larger 
scale study, with improvement in ATEC scales (p < .05), and no within group differences 
were noted in this study.  The Apraxia Imitation Scale was also improved for movement 





larger study, the number of participants is smaller than the quasi-experimental design 
completed by Coben and Padolsky.  In addition, the neurofeedback was a set protocol in 
order to institute the double-blind procedure, which does not allow for more 
individualized treatment interventions.   
Longitudinal Research Studies 
The research studies reviewed above highlight the significant short-term effects of 
neurofeedback in reducing symptoms of ASC.  Kouijzer et al. (2009a) and Coben 
(2009a) evaluated long-term neurofeedback efficacy through follow-up studies conducted 
at 12 months and up to 24 months after treatment.  Coben reported statistically significant 
long-term improvement in 20 individuals with 12 and 24-month follow-ups.  He found 
that children with ASC who received QEEG connectivity guided neurofeedback with at 
least 35 sessions were shown to maintain statistically significant improvements (p < .01) 
with neuropsychological and educational measures along with stabilized QEEG patterns.  
Kouizer et al. (2009a) found statistically significant ( at least p < .05) improvements in a 
12 month follow up for executive functioning including auditory selective attention, 
inhibition of verbal responses, inhibition of motor responses, set shifting, concept 
generation, and planning ability (Kouijzer et al., 2009b).  Kouijzer et al. (2009b) also 
found sustained benefits from neurofeedback in behavioral domains as indicated by 
observers in areas like general communication, pragmatics, social interaction, 
communication, and typical behavior. 
Research Studies Specific to Neurofeedback LZT 
For a complex condition like ASC, research is clearly indicated for individualized 





neuropsychological performance, behavioral and self-report measures, and 
neurophysiological measures like QEEG in order to obtain the best results (Coben & 
Padolsky, 2007).  Specifically, LZT utilizes QEEG post-processing software with Joint-
Time-Frequency-Analysis (JTFA) through a comparative database using Gaussian 
validated norms to assess and train neurofeedback in real time (Collura et al., 2010; 
Thatcher, 2008; Thatcher & Lubar, 2008).  The use of LZT provides a basis for using a 
single measure of analysis, Z-scores, for a variety of statistical analyses of EEG activity 
like coherence, ratios, phase delays, power, amplitude, and asymmetry (Collura, 2008a, 
2008b; Thatcher, 2008).  By identifying normality through Z-scores, the individual is 
capable of matching the state of mind to comparative age-based norms to normalize 
functioning.  Further, there is the possibility of whole-head normalization by utilizing 
posterior to anterior EEG sites during LZT (Collura, 2008b).   
The benefits consist of within and between subject variance within a set age that 
is analyzed by complex demodulation rather than Fourier transform to provide instant 
power and phase analyses (Thatcher & Lubar, 2008).  An example is the Applied 
Neuroscience, Inc. (ANI) Dynamic Link Library (DLL) statistical software which 
consists of 625 people ages two months to 82 years old and has FDA registration (Collura 
& Thatcher, 2006; Collura et al., 2009; Thatcher & Lubar, 2008).  It is capable of 
comparing the individual to the normative database based on age, whether collected 
under eyes open or eyes closed conditions.  The Z scores are computed every 33 
milliseconds to show the NeuroGuide coherences normative Z scores. 
The Z score neurofeedback approach was first utilized in traumatic brain injury to 





2000).  It has now developed into providing EEG metrics, specifically absolute, relative 
power, power ratio, asymmetry, coherence, and phase, and the number of potential 
targets for a 4 channel EEG amplifier will analyze 248 z-scores, 104 power and 144 
connectivity (e.g., coherence) EEG metrics (Collura, 2007; Collura et al., 2009).  Further, 
training options consist of training frequencies up or down, creating ranges such as all Z 
scores within +/- 1 standard deviations, and percentage of Z scores that approach the 
mean or zero.  Z Scores are differentiated by color with yellow being +1 to 1.5 SD, 
orange +1.5 to 2.0 SD, red +2 SD and above, green -1.0 to -1.5 SD, blue-green/cyan -1.5 
to -2.0 SD, and blue -2 SD and below.   
Despite the multiple benefits of LZT, researchers still feel that conventional 
QEEG is indicated in properly assessing and determining the type of feedback protocol 
and a clinician is still needed to determine the type or scope of appropriate neurofeedback 
to be provided (Collura et al., 2009; Collura et al.,, 2010).  With that said, the use of LZT 
simplifies the process of neurofeedback in that it provides a Gaussian distribution for 
individualized training protocols, single metric with Z-scores, instantaneous modification 
of reward and inhibit according to between and within subject variance depending on age 
and eyes closed or eyes open (Collura et al., 2009).  
Gismondi and Thatcher (2009) reported on the efficiency and newly developing 
z-score training that allows for real-time normative database mathematical transforms for 
power and connectivity variables that are related to the theoretical concept of the hubs 
and modules that are functional and not merely one central area or location.  The use of 
LZT helps to improve balance and regulatory improvement in brain function in 





hypercoherence is essentially a cortical compensation in the loss of functional efficiency, 
which is common in neurodevelopmental disorders like autism.  The use of this 
intervention in reducing hypercoherence will normalize brain function in real time.   
Rutter (2009) published the first case study report of a child with profound autism 
using LZT NFT for Brainmaster based on the Z-score DLL from Thatcher’s Neuroguide 
EEG analysis software.  She conducted a QEEG that resulted in identification of elevated 
alpha hypocoherence, high beta (23-27), excess beta asymmetry, and phase activity in the 
fronto-central lobes, whereas there were low delta amplitude and high beta amplitude at 
the sensorimotor strip.  They utilized the “Percent ZOK” Z-score training protocol with 
40-60% reward adjusted during the session using linked-ear reference and ground behind 
right ear on frontal and sensorimotor cortex sites based on the most significant 
dysregulation found on the QEEG.  They had musical tones or visual activated 
reinforcement for the client.  He required desensitization to the experience but was able 
to cooperate with neurofeedback within the initial session lasting 24 minutes with 
sessions ranging from 5-40 minutes.  She found that 10 sessions resulted in less 
aggression, and improved nocturnal enuresis, but increased restlessness and activity, but 
after 20 sessions she noted calmer behavior with less agitation and tics, and he was able 
to sit still and engage in the visual and musical feedback.  Beyond 20 sessions, Rutter 
noted that he was more verbal, improved eye contact, addressing peers voluntarily, 
responded to external stimuli, and improved behaviors at school with social-
communication, in addition to the functional changes in EEG toward the normative 
database.  Rutter’s research helped to highlight both the potential for neurofeedback in 





20 sessions despite the complex neurological problems associated with participant.  This 
study, however, did not provide adequate baseline measures or data analyses that 
objectively evaluated the efficacy of LZT.  For instance, the observations were not 
structured or objective.  There needs to be more studies that provide measurable and 
operationalized behaviors that are being tracked throughout the study. 
The first peer-reviewed publication on the relative efficacy of LZT was completed 
by Collura, Guan, Tarrant, Bailey, and Starr (2010) who reported the results of 19 
submitted case studies, of which three were individuals with ASC.   The montages were 
relatively similar using F3/,/P3/P4, F3/F4/C3/C4, or F7/F8/T5/T6, and all the case studies 
used the “Percent ZOK” program, which rewards the trainee when they maintain Z-
scores (e.g., -1 SD to 1 SD) within a set percentage (e.g., 60% to 80%). All the 
participants showed reduction in abnormal z-scores and improved overall functioning. 
However, the research did not provide statistical analyses and simply provided qualitative 
reports from clinicians who submitted cases. Figure 2 below provides a screen shot from 






Figure 2. Neurofeedback LZT screen with 248 z-scores including connectivity, absolute 
and relative power, and ratio measures (permission by Collura & Thatcher, 2010). 
Number of Sessions Variability in Neurofeedback Research 
 Clinically, the number of sessions for neurofeedback varies greatly depending on 
the type of condition, severity, and procedure used.  In research on individuals with ASC, 
neurofeedback has ranged from just 20 sessions (Coben & Podolsky, 2007) to as many as 
100 sessions (Thompson & Thompson, 2003b).  When symptom-based protocols were 
implemented (i.e., training based on symptom self-reports), the number of sessions 
reported is greater than those that implemented comprehensive neuropsychological 
testing and QEEG-guided protocols (Coben & Podolsky, 2007).  Single channel 
approaches, such as training at C3 or C4, also require the greatest number of sessions in 
order to exhibit improvement (Thompson & Thompson, 2003b).  In one study regarding 





after 10 sessions, but received over 20 sessions to make significant gains (Rutter, 2009).  
Coben and Podolsky explained that the fewer sessions were needed due to the use of 
individualized neurofeedback approaches using bipolar protocols (i.e., one active sensor 
site and one reference site located over a specified brain site) as opposed to unipolar 
protocols (i.e., one active sensor over a brain region and a reference to the ear).  The use 
of neurofeedback LZT may provide enhanced training over four active sites instead of 
two sites along with individualized training in real-time.  Therefore, neurofeedback LZT 
may provide efficacy in a shorter period of time.   
Neurofeedback Adverse Effects 
Neurofeedback has a high benefit-risk ratio (89:1) compared to other 
interventions like psychopharmacological interventions or dietary supplements for ASC 
(Coben & Padolsky, 2007).  According to parent reports, neurofeedback provided the 
most benefits and minimal to no adverse effects compared to all other interventions for 
ASC (Coben & Padolsky, 2007).  However, there are always potential risks in changing 
brain function when it is not individualized using multimodal assessment strategies to 
determine appropriate site locations and feedback protocols (Hammond & Kirk, 2008).  
Most recently there is a trend for psychologists and researchers in being more assertive in 
identifying and reporting negative iatrogenic effects of therapeutic techniques (Barlow, 
2010).  The need for developing systems for monitoring adverse effects and randomized-
controlled trials (RCT) are critical for examination of potential side effects as a result of 
psychological interventions (Dimidjian & Hollon, 2010).  
With regard to LZT training, a compilation of case studies found that there were 





score training with a wide threshold (e.g., +/- 3 SD) could potentially lead to abreactions 
and unnecessary training.  Also, Rutter (2009) identified initial worsening of symptoms 
such as increased activity when using LZT, but in later sessions, she found a significant 
decrease in symptoms.  Among reports from NFT on an internet list serve, clinicians 
providing neurofeedback noted adverse effects such as vocal/motor tics, muscle twitches, 
somatic complaints, enuresis, incontinence, epileptiform activity, fatigue, anxiety, 
agitation/irritability, obsessive-compulsiveness, depression, mania, cognitive 
inefficiencies, inattention, poor concentration, insomnia/hypersomnia, regression, and 
seizures (Hammond & Kirk, 2008).  Also, it was identified that poorly planned 
interventions may create a decrease in executive functioning performance (Knezevic et 
al., 2009, 2010).  However, these reports were subjective and had no specific tool to 
assess adverse effects or research method to adequately support these findings.  Further, 
the main factor in adverse effects were a result of using protocol-based neurofeedback as 
opposed to individualized neurofeedback training that incorporates a comprehensive 
evaluation to determine the best course of treatment. Hammond and Kirk (2008) 
suggested that many of these protocols served to reinforce certain bandwidths that may 
have exacerbated symptoms rather than inhibiting EEG activity that is seen as 
problematic.  Therefore, monitoring these symptoms is essential during neurofeedback.  
Gap in the Neurofeedback Research on Autism 
The biofeedback monograph was created to assess the level of efficacy according 
to standards of research for evidenced based practice of biofeedback (LaVaque et al., 
2002).  At the time, the monograph cited that autism was considered insufficiently 





neurofeedback was still in the process of developing standards for research and 
identifying efficacy in various neuropsychological disorders like ASC.  However, since 
that time, there have been multiple case studies, case series, presentations, quasi-
experimental studies, and double blind experimental studies that support a level of 
probably efficacious in treating ASC (Coben & Padolsky, 2007; Jarusiewicz, 2002; 
Knezevic et al., 2009, 2010; Pineda et al.,, 2008; Yucha & Montgomery, 2008).  Still, 
there is a lack of empirical support for interventions in adults with ASC that have been 
found effective in reducing symptoms in children with ASC (Roy et al., 2009; Shea & 
Masibov, 2005; Wolf & Paterson, 2010).  For example, neurofeedback has shown success 
in treating symptoms associated with ASC through multiple case studies and controlled 
trials, but majority of participants consisted of young children to early adolescents 
(Coben et al., 2010).   
Some researchers like Thompson and Thompson (2003b) have found subjective 
improvement with psychosocial functioning into adulthood indicated by improved 
college and employment performances.  When comparing if there were differences in the 
efficacy of neurofeedback for age or level of intellectual functioning, Knezevic, 
Thompson, and Thompson (2009, 2010) found no statistically significant differences on 
the ToLDX, a test of executive functioning.  These results suggest that varying ages and 
level of intellectual functioning show equally positive results with NFT.  In a 
retrospective case series study, Thompson et al. (2010b) evaluated a combination of 
neurofeedback, metacognitive strategies, and traditional biofeedback in 159 participants, 
of which 12 were adults, and they found that neurofeedback improved neurocognitive 





be a prospective quantitative study that specifically evaluates the level of efficacy with 
adults for neurofeedback LZT. 
Lastly, although there have been multiple case studies mentioned in this review, 
they have not followed quantitative experimental formats recommended by Blampied, 
Barabasz, and Barabasz (1996) or Kazdin (1982) such as multiple baseline AB designs, 
and because of this, it has led to subjective interpretations and qualitative reports.  
Further, Kazdin (1982) discussed biofeedback and psychophysiological studies are at an 
advantage in single-case research because automated measurement devices like EEG 
recordings are optimally objective, acquired in repeated measures, and reliable for data 
acquisition, which are easily evaluated in visual inspection formats.  Despite the benefit 
of single-case research designs in neurofeedback research, none of the case studies noted 
above included baseline measures or quantitative procedures that allowed for causal 
inferences and the ability to reject or accept the null hypotheses.  Another rationale is that 
applied research settings like local clinics and private practices often have imitations 
associated with access to larger sample sizes, so single-case research seems to be the 
preferred method for evaluating efficacy of interventions like neurofeedback.  In 
addition, given the fact that ASC carries such a wide variety of social and behavioral 
symptoms (APA, 2000), the samples used in the larger studies are likely heterogeneous 
with great variability in each participant’s symptom profile.  Therefore, there is a need for 
increased utility of single-subject research in ASC to evaluate individual characteristics 
and changes in the participant’s profile (Shadish et al., 2002). 
Summary and Transition 





the rationale of this proposal.  Specifically, ASC is a neurodevelopmental disorder with 
challenges that maintain into adulthood and the rising prevalence rates and costs 
associated with ASC only increase the need for effective interventions beyond childhood.  
The literature review covered autism research that identified significant and broad 
impairments in neurophysiological functioning particularly EEG connectivity, 
neurocognitive deficits in information processing and executive functioning, impaired 
empathy and comprehension of the intentions of others, rigidity in routines such as fixed 
areas of interests, obsessive stereotypic behaviors, and along with a number of comorbid 
symptoms such as inattention, impulsivity, depression, anxiety, and mood instability.  
With all these concerns in ASC, there is a need for preliminary investigations of newly 
developing interventions like neurofeedback LZT particularly with measures that 
comprehensively explore its detailed effects.  Although there are a number of 
neurofeedback studies finding significant improvement in children with ASC, there are 
only a few retrospective studies that have evaluated it in adulthood.  Further, there are 
presently no quantitative research studies evaluating the effects of neurofeedback LZT.   
Chapter 3 will use this research as a direction for the proposed methodology in exploring 





Chapter 3: Research Method 
Introduction to the Research Method 
The purpose of this study was to evaluate whether neurofeedback LZT in an adult 
with ASC would result in a reduction of autistic and neuropsychological symptoms and 
improvement in general intelligence, neurocognitive abilities, and brain function as 
measured by QEEG and LORETA.  In Chapter 3, the principal investigator provided the 
research design overview, setting, participant recruitment, sample size, data collection, 
analysis, instrumentation, materials, procedure, research questions and hypothesis, 
overview of dependent variables, and protection of the participant will be detailed. 
Research Design Overview 
Efficacy of neurofeedback in children diagnosed with autism has been well 
researched in qualitative case studies, with results indicative of improved 
neuropsychological and neurophysiological functioning (Beaumont & Montgomery, 
2005; Cowan & Markham, 1994; Rutter, 2009; Sichel et al., 1995; Thompson & 
Thompson, 2003).  Although qualitative and retrospective case study research is 
important and offers support for clinical utility, more rigorous research designs such as 
mixed methods, repeated measures single-case research, quasi-experimental, and 
experimental research designs are needed to further validate and identify clinical efficacy 
of neurofeedback through quantitative analyses and causal inferences (Blampied et 
al.,1996; Coben et al., 2010).  The most important future direction for validation of 
neurofeedback in ASC is to evaluate the specificity of the effects in neuropsychological 
symptoms, neurocognitive abilities, and brain function in autism (LaVaque et al., 2002).   





with ASC in quasi-experimental research studies with either QEEG guided or symptom-
based protocols (Coben & Padolsky, 2007; Jarusiewicz, 2002; Kouijzer et al., 2009b).  
There has been only one study to date in which researchers used randomized double-
blind research (Pineda et al., 2008).  Within the specific approach of neurofeedback LZT, 
there have been only two peer-reviewed articles investigating the efficacy of LZT in 
children with neurodevelopmental disorders using qualitative case study research 
(Collura et al., 2010; Rutter, 2009).  These articles consisted of qualitative observer 
reports and pre and post QEEG data, but the researchers did not implement more rigorous 
research methods, such as repeated measures single-case research using validated and 
reliable report measures.  Also, because ASC is heterogeneous in symptoms and 
functional level (APA, 2000), it made sense to evaluate the effects in a single case 
particularly because of the potential predictive variables—age and intellectual level 
(Coben et al., 2010).   
The study was structured as a multiple baseline AB research design to evaluate 
changes associated with neurofeedback in an adult with ASC (Creswell, 1994; Kazdin, 
1982; Shadish et al., 2002).  The first phase consisted of recruiting volunteer adults who 
have been diagnosed with autism, a convenience sample from a local neurofeedback 
clinic.  The participant who qualified was welcomed into this study and provided 
information on the informed consent process, provider’s qualifications form, release of 
information allowing disclosure to his medical and therapist providers, limits to 
confidentiality, IRB research consent and disclosure, and consented to assessments and 
testing.  Following the initial consents, the participant commenced with five baseline 





a neurocognitive battery, three baseline measures of intelligence, and pretreatment QEEG 
and LORETA maps.  Neurofeedback LZT training consisted of 20 sessions in a clinical 
setting, and was within the number of sessions of neurofeedback LZT that has shown a 
treatment effect—as low as 10 sessions have demonstrated significant improvement in 
ASC (Collura et al., 2010; Rutter, 2009).  The neurofeedback intervention was conducted 
by a neurofeedback clinic in rural Michigan and was separate from this research study.  
Testing occurred throughout treatment.  Visual inspection was used to assess change and 
clinical significance between the baseline phase and neurofeedback phase with trending 
data point graphs (Blampied, 2000; Fisher, Kelley, & Lomas, 2003; Kazdin, 1982).  
Given that neurofeedback researchers have demonstrated long-term effects on 
neuropsychological functioning (Kouijzer et al., 2009a; Coben, 2009a); using another 
single-case research design such as ABAB was not applicable to this research study.  
Setting and Participant Recruitment 
 This section includes details regarding the type of research setting, participant 
inclusion and exclusion criteria, rationale for sample size, informed consent process, and 
confidentiality.  The sample size is explored in detail regarding investigators who support 
single-case research in conditions like autism and interventions like neurofeedback.  The 
overall purpose of this section was to provide an overview of the research project’s 
environment and participant.  
Research Setting 
The setting was in a rural community of the Lower Peninsula in northwest 
Michigan.  The research was conducted at a local neurofeedback clinic with the necessary 





adequate lighting, handicap accessible space, and maintained a temperature of 
approximately 20 °C to prevent sweating during sensor placement and to reduce artifact 
during administration of neurofeedback.  Neurofeedback clinic consultants volunteered 
and donated supervision, neurofeedback services, consultation, and direction for the 
research study.  The community partnership with a neurofeedback clinic was essential 
because it provided the neurofeedback, acquisition of QEEG, and other data important to 
the study.  The principal investigator had no prior or existing business relationship with 
the neurofeedback clinic that might be considered a conflict of interest for this study.  
The clinicians of the neurofeedback clinic and the principal investigator are Board 
Certified in Neurofeedback (BCN) by the Biofeedback Certification International 
Alliance (BCIA).  The BCN certification requires completion of 36 hours of didactic 
education in neurofeedback, coursework in physiology, 25 hours of mentoring, 100 client 
sessions, case conferences, and passing the written certification examination.  The 
rigorous standards set by the BCIA are critical for professional competency and ethical 
practice in the application of neurofeedback in research for this research study.    
Participant Recruitment 
The convenience sample consisted of a single participant who was recruited by a 
continuous 2-week advertorial by the neurofeedback clinic.  Only prospective 
neurofeedback clients with ASC who meet the inclusion criteria were offered information 
about the study.  Further, only participants who sought neurofeedback at the clinic were 
considered.  The neurofeedback clinic consultants were responsible for screening and 
selecting the potential participants for consideration without any input from the principal 





advertisement (see Appendix C).  Following the screening and when the interested 
participant was identified, he was referred to initiate the study.  The research study 
consisted only of the interview, testing, and assessment procedures; the neurofeedback 
itself was provided as a clinical service separate from the research procedures. 
Inclusion criteria.  The potential participants consisted of individuals of either 
sex or any ethnicity over the age of 18.  They needed to be taking less than three 
medications-no specific medications were part of the exclusionary criteria (Coben & 
Padolsky, 2007; Johnstone, Gunkelman, & Lunt, 2005; Townsend, 2007).  Other 
inclusion criteria were at of least average intellectual functioning or a 100 IQ within a 
standard deviation of 15, and competent to consent to research participation.  The 
candidate needed to have a diagnosis from a healthcare professional of an ASC, which 
included autistic disorder, Asperger’s disorder, childhood disintegrative disorder, and 
PDD NOS (APA, 2000, 2010).  Due to the high male-to-female ratio (APA, 2000; CDC, 
2009; Klin, McPartland, & Volkmar, 2005), the prospective participants were all males, 
and although all races and ethnicities were included, the participants were European 
American because of the population demographics of this specific rural area in Michigan.  
The research procedures did not exclude a participant based on ethnicity, race, sex, 
religion, or education. 
Exclusion criteria.  The participants excluded were those who were under the 
age of 18, and/or those who were prescribed more than three medications, and/or those 
with a level of intellectual functioning below average or lower (i.e., 85 IQ) and who were 
not competent to consent to research participation.  Due to the proposed changes for 





did not qualify as an ASC.  Individuals who were non-English speaking, pregnant, elderly 
(ages 65 years or older), or who lived in a residential facility were excluded from this 
study.   Individuals who scored in the severe range on the Neuropsych Questionnaire for 
Depression would have been referred for psychological treatment services; however this 
did not occur.  Exclusion criteria were provided in the advertisement.  Following the 
initial discussion of the advertorial, one participant was excluded because he was being 
incarcerated and was provided the following statement, “Unfortunately due to the specific 
nature of the study, I am only able to accept people who meet set criteria.  Thank you for 
offering your time and considering this project.”    
Informed consent. The informed consent process was ongoing throughout the 
study in order to allow for continuous dialogue with the participant regarding the research 
study.  At the initial session as well as at each research-related testing appointment the 
participant was informed that this was a clinical research project and he was only 
consenting to testing, assessment, and interviews for the study.  The consent form was 
presented, read, and signed by the participant during the first session (see Appendix D).  
The principal investigator read the consent form aloud and addressed the participant’s 
questions and concerns in order to ensure comprehension.  The participant had an 
advocate, which was his mother, who acted as a witness during the informed consent.  
During the sessions, the participant was assessed for adverse effects and informed of his 
ability to retract consent and terminate participation at any time.  The informed consent 
process also included providing information on neurofeedback, but it was made clear that 
the research study was investigating changes associated with the clinical training, and 





Confidentiality.  The participant was assigned a case number to preserve 
confidentiality.  The case number was used on all study-related documentation as well as 
computer files, which were kept on a secured password protected computer.  IRB 
guidelines for consent and disclosure of data are provided in Appendix E. All original 
research documents including the ID key that associates case numbers with names were 
stored in a locked filing system and within a secured password protected computer.  
Identifying information was destroyed when data collection was completed. 
Sample Size 
The proposed study utilized a single-case research design that consisted of one 
participant.  The decision for single-case research was based on the ability to provide 
causal inferences with a rejection of the null hypothesis, visual inspection of effects 
through graphs, and replication to develop reliable and consistent findings in multiple 
cases or larger sample studies (Blampied, 2000; Kazdin, 1982).  Single-case research 
allows for preliminary investigations regarding the effects of an intervention prior to 
more rigorous research methodology such as randomized controlled trials.  Researchers 
like Skinner (1948) have used single-case research to develop learning theories that have 
been generalized from animals to people in applied research settings.  Further, 
neurofeedback is based on operant conditioning and other learning theories that have 
used single-case research as the primary research approach.  It is an important method in 
psychological research, because it focuses on the individual rather than averaging group 
processes, and single-case research has been often used in research with biofeedback 
interventions (Kazdin, 1982).  Single-case research is particularly important when 





symptom profiles.  Some researchers have suggested that studying ASC in a group 
analysis actually reveals little information due to the variety of differences in cognitive 
functioning (Towgood, Meuwese, Gilbert, Turner, & Burgess, 2009).  However, when 
the analysis is based on single-case research, Towgood et al. (2009) found more 
informative details regarding cognitive profiles amongst individual participants with ASC 
offering more data to support the complexity of ASC.  Therefore, using single-case 
research avoids the averaging and loss of information that might be found in this 
particular study.   
Secondly, neurofeedback studies have historically consisted of smaller sample 
sizes (Rojas & Chan, 2005), and despite these small samples, the researchers have 
demonstrated high effect sizes for neurofeedback in neurodevelopmental conditions like 
ADHD and ASC (Arns, Ridder, Strehl, Breteler, & Coenen, 2009; Coben, 2009; 
Monastra, Monastra, & George, 2002; Thornton & Carmody, 2008).  Monastra et al. 
(2002) reported large effect sizes of 2.22 for treating inattention and 1.36 for 
hyperactivity.  In a recent meta-analysis research of neurofeedback in ADHD, Arns et al. 
(2009) identified effects sizes that averaged around .81 for inattention, .69 for 
impulsivity, and .40 for hyperactivity.  In treatment for traumatic brain injuries (TBI), 
Thornton and Carmody (2008) reported effect sizes for neurofeedback protocols at .55, 
and when quantitative EEG assessments guided training, the effect size was large at 
around 2.61 for treating symptoms related to the condition.  Coben (personal 
communication, July 21, 2009) calculated a large effect size of 1.05 in a cumulative 
sample of 92 research participants with ASC using QEEG-guided neurofeedback, which 





measures.  Therefore, neurofeedback researchers have consistently found high effect 
sizes despite these smaller sample sizes.   
Another rationale in choosing a single participant is that it protects against Type II 
error rates by analyzing multiple baseline measures of dependent variables on an 
individual level and provides an opportunity to more fully analyze changes associated 
with neurofeedback on subjective and objective measures. For these reasons, single-case 
research has multiple advantages and was the best approach for the specificity of this 
research. Further, empirically supported interventions for ASC have been validated 
through the single-case research designs for several decades (Smith, 2008).  Almost 90% 
of behavioral interventions for ASC have been evaluated through single-case research 
(Matson, Matson, & Rivet, 2007).  The benefit of such designs is that they have the 
individual become his own experiment with a baseline control and experimental phase to 
identify an effect.  Lastly, single-case research has validated approaches like Applied 
Behavioral Analysis as well as invalidated approaches like facilitated communication 
(Smith, 2008).  Thus, single-case research is a method that is effective in evaluating the 
null hypotheses and has been used to effectively validate interventions in ASC. 
Data Collection and Analysis 
The data collection began with demographic and descriptive information 
including gender, age, handedness, level of education, race/ethnicity, medications, 
supplements, and alcohol/drug use including caffeine and cigarettes.  The participant was 
provided a screening form found in Appendix F.  A release form in Appendix G was 
signed to allow the primary investigator to contact the participant’s health care 





and records retrieved were kept in a locked cabinet.  The collection process began by 
phone, mail, or direct face to face interviews. 
Although there are statistical methods such as autocorrelation in single-case 
research, researchers have found that these techniques in single-case research are 
problematic and tend to skew effect sizes because they violate assumptions of statistical 
techniques (Parker et al., 2005).  The other main analysis for single-case research is 
visual inspection, which has been viewed as an effective and accurate way to analyze the 
effects of neurofeedback (Kazdin, 1982).  Visual inspection offers the ability to 
determine changes of performance through data pattern analysis over time through 
exploring consistency in changes. A recent study found high interrater agreement for 
visual inspection when considering mean shift, variability, and trend across phases 
indicating consistency in interpretation of single-case data (Kahng et al., 2010).  Related 
to this study, researchers have utilized visual inspection analysis effectively and validly 
in psychophysiological research (Schoen, Miller, Brett-Green, & Hepburn, 2008) as well 
as new and innovative interventions for ASC (Taylor et al., 2009).  In addition, visual 
inspection is considered a conservative approach compared to statistical analyses that 
tend to identify significant changes when there are minimal or slight differences in data 
(Fisher, Kelley, & Lomas, 2003; Kahng et al., 2010).  For these reasons, visual inspection 
was used to plot data points across time through connecting lines through each data point 
by phase, and the graph was evaluated visually for the slope trend and mean baseline 
compared to the neurofeedback phase (Kazdin, 1982).   
Fisher et al. (2003) developed a structured technique called the conservative dual 





evaluating treatment efficacy when a set number of data points that fall above the linear 
regression trendline based on the binomial test and the same number of data points also 
had to fall above or below the mean line of the baseline data.  The CDC went further by 
raising the two criterion lines, mean and trendline, by .25 standard deviations calculated 
from the baseline data.  Fisher et al. applied the Monte Carlo Validation of CDC and 
found that it was the only visual inspection procedure that guarded against Type I and II 
error rates with and without autocorrelation and higher power levels than statistical 
procedures.  The authors also found that applying a dual criterion provided greater 
improvement in determining an accurate treatment effect based on this method much 
better than other ways such as the split-middle technique proposed by Kazdin (1982).  
Recently, Stewart, Carr, Brandt, and McHenry (2007) found that the CDC improved 
substantially improved visual inspection accuracy over traditional subjective 
interpretations data trends.  When the CDC lines were removed, students had increased 
false alarm rates suggesting the need for methods like CDC in visual inspection to 
prevent Type I errors.  Keller (2007) found that the CDC had consistency with statistical 
process control of up to 54%, and that the CDC was more conservative when determining 
treatment effects in single subject studies.    
Figures 3 and 4 below depict examples of significant and not significant effects, 
respectively, using the CDC method on the dependent variable NPQ-LF Asperger’s 
index.  The combination of the mean and linear regression lines of the baseline data with 
a .25 SD modification provides two strict criterions to evaluate the effect of 





points in this study needed to fall above or below the modified mean and regression lines 





















































































Lastly, pre and postdata were charted for the TONI and QEEG maps for visual 
inspection of change.  A simple line graph plotting three baseline and three treatment 
phase data points were used for the TONI.  A significant change in the TONI was 
analyzed by visual inspection with an observable change from the baseline mean and 
trendline to the treatment phase (Kazdin, 1982).  For the QEEG maps, data were 
reviewed via Neuroguide software for changes in power and other measures.  Changes in 
absolute power or relative power values were explored through visual inspection using 
Neuroguide’s Neurostat software program of pre and post-QEEG maps.  Figure 5 is an 
example of a summary Z-scored FFT QEEG maps of absolute power, which is the square 
of the magnitude indicating the amount of energy across the frequency bandwidths.  In 
addition to serving as a tool for change, these maps were used to guide the neurofeedback 
practitioner for determination of which sites to choose.   
 
    
    
Figure 5. Example of QEEG maps’ absolute power by the principal researcher. 
 
Instrumentation and Materials 
Computer Equipment 





17.3” HD+ Bright View LED Display, AMD Phenom II N850 Triple-Core processor 
2.20 GHz, 4.00 GB RAM, 640 GB hard drive, 64-bit operating system, Windows 7 
software, and Blu-Ray and DVD disc drives.  It has a Fingerprint Reader that enhances 
protection of confidentiality and privacy of the data.  The computer-based neurocognitive 
test has a standardized keyboard in order to improve the reliability of test administration 
in the same method that was used in the validity and reliability research studies. 
Software Programs 
 The CNS Vital Signs (CNSVS; 2010) was the software used for the Neuropsych 
Questionnaire (NPQ; Gualtieri, 2007) and CNSVS Neurocognitive Test.  This software 
requires at minimum Windows based software, 2 GH Pentium Class Machine, 256 MB 
RAM, 15 MB hard disc space, and 32 bit Super VGA.   The software provides access to 
data collection of the CNSVS NPQ and Neurocognitive Test for each participant as well 
as summaries in Adobe formatted files.  The participant was provided a series of tests on 
the computer screen that consisted of questions with multiple response options, shapes, 
words, and directions with count downs prior to each testing section. 
Neuropsych Questionnaire 
The NPQ (Gualtieri, 2007) is a computer-based neuropsychological screening 
instrument consisting of the NPQ-Long Form (LF) 207 questions, and Short Form (SF) 
that has 45 questions.  For the purpose of this research, the NPQ-LF was used for 
baseline and postmeasures (see Appendix H).  The rationale for using the NPQ-LF in this 
research project was that it offers ranges that are sensitive to treatment effects and 
consists of Asperger’s, autism, ADHD, anxiety, depression, and mood stability indices, 





2000; Bellini, 2006; Shtayermman, 2008; Volkmar & Klin, 2005).  The index scores are 
categorized as not significant at 74 or lower, mild scores are in the 75-149 range, 
moderate scores fall in the 150 to 224 range, and severe scores fall in the 225 to 300 
range.   
Validity. The questions on the NPQ were developed through matching up to 75% 
similarity with common screeners used in clinical practice such as the Brief Psychiatric 
Rating Scale, Beck’s checklists, and others.  Each symptom is rated on a Likert scale 
from zero to three reflective of “not a problem,” “a mild problem,” “a moderate 
problem,” or “a severe problem” respectively (Gualtieri, 2007, p. 4).  The Beta version 
was administered to 814 adults, aged 18-80 years, 45% male, and 90% European 
American.  Although this is not reflective of a multicultural sample, many of the 
questions were similar to scales that were normed using a more multicultural sample.  
Also, this research project was conducted in a rural area that has a majority European 
American sampling population, so the norms would generalize to the participant in this 
study. 
Reliability. Gualtieri (2007) found that there was high internal consistency for the 
scales included in the final version of the NPQ, test-retest reliability for 74 patients in a 3 
month period was significant (p = .0001) for an average r = .74 interrater reliability on 
the same day.  Two different observer reports were also significant (p = .0001 to .002) for 
an average r = .54, and sensitivity to treatment with studies including pre and 
postinterventions and experimental-control studies showing changes for those that 





scales ranges from r = .33 to .96, test-retest reliability ranges from r = .53 to .82, and 
interrater reliability ranges between r = .39 to .74.   
CNSVS Neurocognitive Test 
The CNSVS Neurocognitive Test (Gualtieri & Johnson, 2008; Gualtieri, Johnson, 
& Benedict, 2004) was developed to detect neurocognitive impairments and is comprised 
of the Verbal and Visual memory, Finger Tapping, Symbol Digit Coding, Stroop, 
Shifting Attention, and the Continuous Performance Tests, which provide 17 primary 
scores and five domain scores.  The indices are based on standard scores averaging at 100 
with a standard deviation of 15 (Gualtieri & Johnson, 2008; Gualtieri et al., 2004).  The 
subtests in the CNS VS consist of Symbol Digit Coding, Shifting Attention, Finger 
Tapping, Stroop Test, Continuous Performance Test, and Visual and Verbal Memory 
tests.   
Validity. The norms were validated using 489 normal individuals ages 9-89, and 
standardized against other computerized tests (Gualtieri et al., 2004).  The CNSVS also 
provides differential diagnostic categorizations between ADHD, traumatic brain injury, 
and dementia for over 1,000 patients.  In a cross-sectional naturalistic study of 141 brain 
injury patients ages 18-65 years, the CNSVS was able to differentiate between level of 
traumatic brain injury (TBI) especially with regard to psychomotor speed and cognitive 
flexibility (Gualtieri & Johnson, 2008).  The domain score were statistically significant (p 
< .05) for distinguishing TBI with control participants.   
Reliability. The CNSVS is considered reliable between a 12-day interval retest (r 
= .45-.84, N = 155; Gualtieri et al., 2004).  Recently, CNSVS has been used to determine 





such as the CPT, ST, verbal and visual memory, and SDC (Kouijzer, de Moor, Gerrits,  
Buitelaar, et al., 2009a; Kouijzer, de Moor, Gerrits, Congedo, et al., 2009b).  The 
researchers showed that there were statistically significant differences between the 
treatment and control groups on three separate administrations with a pre/postmeasure 
over 3 months and again after 12 months, demonstrating sustained for the experimental 
group.  Therefore, it was a useful measure for testing neurocognitive changes in the 
participant of this study during the course of neurofeedback.  
Test of Nonverbal Intelligence 
Brown, Sherbenov, and Johnsen (2010) developed the Test of Nonverbal 
Intelligence (TONI) as an overall cognitive ability measure for those who have sensory 
deficits or have language difficulties or differences, which are concerns for individuals 
with ASC (APA, 2000, 2010; CDC, 2007, 2009).  The TONI-4 is the latest edition, which 
reduced biases and increased validity and reliability associated with certain demographics 
such as gender and ethnicity (Johnsen et al., 2010).  The TONI was developed through 
307 items that were reviewed by experts in psychological testing and presently contains 
60-items for each form.  This measure was selected for use in this study based on an 
unpublished study by Berman, Sudol, Miller, and Berman (2005) with 10 children with 
ASC who were provided neurofeedback.  Berman et al. (2005) found statistically 
significant improvement (p < .005) in pre and post TONI-3 scores for participant.  
Neurofeedback may improve global intelligence scores in children with ASC, and was 
considered a measure that may be helpful in evaluating the efficacy of neurofeedback in 





Validity. The TONI was normed across two time periods and administered to a 
total of 3,451 participants (Brown et al., 1997), and the most recent version TONI-4, was 
normed on a sample of 2,272 people in 32 states and included stratification of the sample 
(Brown et al., 2010).  The TONI is largely representative of the U.S. population by 
geography, gender, community type, ethnicity/race, disability, and socioeconomic status, 
and age groups ranging from ages 6-0 to 89-11.  The TONI is significantly correlated to 
the Wechsler Adult Intelligence Scale-Revised, with correlations of .57 and .58 for verbal 
and .75 and .76 for performance on the A and B forms respectively, correlation for 
general aptitude was a median of .52 (Brown et al., 1997).  The item analyses was 
conducted using a point-biserial correlation, and the TONI was identified having .33 or 
higher and p value mean of .50.  The construct validity consisted of six types of evidence: 
observed relationship between TONI and intelligence, correlation to school performance, 
performance ranges from gifted to significantly impaired individuals coincided with what 
was expected, strong predictor of full battery of intelligence testing, indicated by a single 
strong factor, and item point biserials by age group of .49 for form A and .50 for form B.  
The correlation between the TONI-4 and TONI-3 is very large with correlation 
coefficients of 74.   
Reliability. Reliability was evaluated in four ways for the TONI-4: coefficient 
alpha, alternate forms, test-retest, and interscorer.  The TONI-4 maintained high 
reliability at an average of 96 coefficient alpha on both forms with a standard error of 
measure from two to four (Brown et al., 2010).  Alternate-forms correlation averaged .84 
for all subjects.   The test-retest correlations with 1 to 2-week separation correlation 





reliability held near-perfect .99 correlation coefficient.  The TONI has maintained 
reliability since early versions of the test (Brown et al., 1997). 
Quantitative Electroencephalogram 
The participant received a QEEG assessment prior to neurofeedback training and 
at the conclusion of training. QEEG assessment is a measurement of real-time EEG 
function at multiple locations on the scalp simultaneously (Thatcher & Lubar, 2008). In 
addition to a measurement of functional patterns at each individual location, a measure of 
the interplay among the sites, including timing and similarity, is obtained (Thatcher & 
Lubar, 2008). EEG measures include absolute power, relative power, power ratio, 
coherence, asymmetry, and phase within eight bandwidths and individual bins (Thatcher 
& Lubar, 2008).  
The QEEG assessment was implemented as directed by the standards set forth by 
Hammond and Gunkelman (2001). Prior to the EEG assessment, the participant was 
provided with information on how the assessment was done and given instructions on 
how to prepare for the assessment. He was instructed to avoid alcohol and over-the-
counter medications prior to the assessment, to get at least 8 hours of sleep the night 
before, to thoroughly wash his hair with shampoo the morning of the assessment and to 
avoid the use of hair products. During the pre and postassessments, an appropriately sized 
elastic cap fitted with EEG electrodes (ECI Electro-Cap, Electro-Cap International, 
Eaton, OH) was placed on the participant’s head and adjusted for symmetry and proper 
electrode placement. The electrodes were filled with conductive gel using a syringe and 





EEG data were recorded with a Lexicor 24-channel digital EEG recording device 
using Neurolex™ software. The EEG recorded at 256 samples per second with high pass 
filter in the off position in two conditions–eyes closed for 10 minutes and eyes open for 
10 minutes. The clinician paused periodically to ensure participant alertness and comfort.  
The EEG records were visually and automatically edited for artifact and processed using 
the Neuroguide Deluxe software and the Lifespan Normative Database (Applied 
Neuroscience, Inc.).  This software has been normed with 625 individuals ages 2 months 
to 82 years with EEG acquisition eyes open or closed (Collura & Thatcher, 2006; Collura 
et al., 2009; Thatcher & Lubar, 2008).  In addition to Neuroguide software, low 
resolution brain electromagnetic tomography (LORETA) is a functional brain imaging 
method that statistically maps neurophysiological processes through a three-dimensional 
anatomical generic model of the brain (Pascual-Marqui, Michel, & Lehmann, 1994).  The 
LORETA and QEEG maps were used to guide the training protocol and track changes in 
neurophysiological functioning.  These measures included probability measures of .001 
to .06 ranges for significance.  Significant changes were noted by visual inspection in 
changes of color.   
Monitoring of Side Effects Scale 
The face validity for the Monitoring of Side Effects Scale (MOSES; Kalachinik, 
2001) was derived from peer-reviewed articles for side effects of psychopharmacologic 
and anticonvulsant medications.  The MOSES was helpful in comparing side effects 
relative to medication interventions in autism.  The scales range from zero (none) to four 
(severe), and are divided in the following categories: Ears/Eyes/Head, Mouth, 





Skin, and Psychological.  The procedure takes up to 5 minutes, maintains a high 
sensitivity for identifying side effects, and low specificity or false negatives/positives.  
For the purpose of this study, the only areas that were evaluated were the sections on 
Neurological and Psychological side effects each week during the baseline and 
neurofeedback phases (see Appendix I).   
Overview of Dependent Variables 
Table 1 provides the overview of the DV that were examined in this study.  It is 
important to note that Chapter 2 provides a detailed account of the complexity of ASC.   
Included in the literature review, autism has symptoms associated with deficits in social-
communication, ADHD, mood dysregulation, executive functioning, processing of 
information, and neurophysiology.  These DVs provide a comprehensive assessment of 
neurofeedback’s effect on ASC symptoms and related issues.  Coben and Padolsky 
(2007) and other researchers in neurofeedback have used similar multiple baseline 
measures in order to adequately cover the broad deficits in ASC.  Unique to this study 
was that this was the first neurofeedback research in ASC to use measures assessing 
comorbid disorders of autism and self-reports by the participant rather than other 
reporters like parents and teachers.  This provided the opportunity for the participant to 
quantify changes in overall mental health related issues particularly in areas like 











 Variable Assessment 
Core Autism Symptoms Asperger’s NPQ-LF 
Neuropsychological Index 1 ADHD NPQ-LF 
Neuropsychological Index 2 Mood Stability NPQ-LF 
Neuropsychological Index 3 Anxiety NPQ-LF 
Neuropsychological Index 4 Depression NPQ-LF 
Neurocognitive Ability 1 Executive Function CNSVS 
Neurocognitive Ability 2 Processing Speed CNSVS 
Intelligence Measure Nonverbal Intelligence TONI 
Neurophysiological Function  QEEG Neuroguide 




Phase A consisted of the initial convenience-criterion sample selection of a 
volunteer participant solicited by the neurofeedback clinic.  The principal investigator 
had no input to the manner in which the participants was identified.  The adult participant 
with ASC accepted into the study was willing to participate in testing and assessment 
procedures while he received neurofeedback by the clinic.  It was assumed that the 
participant hoped to receive benefit from the neurofeedback in improving symptoms.  If 





crisis assessment), then he would have been referred as needed by clinic.  This was not 
the case for the participant who consented for the study. 
The initial step required a verification of the ASC diagnosis by a licensed 
healthcare professional, and a release form was used to access only the evaluation 
confirming the diagnosis, which was confirmed.  The pretest or baseline consisted of 
gathering pertinent background information and pretesting measures.  At the initial 
session, the participant provided informed consent and an explanation of the assessment 
and testing, which consisted of the measures listed below.  The initial evaluation required 
a total of 90 to 120 minutes and was separated in three individual sessions to prevent 
fatigue from the testing and assessment procedures. 
The measures and administration time included 
1.  The NPQ- LF (approximately 15 minutes, baseline consisted of five 
administrations, and reassessed five times during the neurofeedback phase). 
2. CNSVS Neurocognitive Test (approximately 15 minutes, baseline consisted 
of five administrations, and reassessed five times during the neurofeedback 
phase). 
3. TONI (approximately 15 minutes, three times in baseline and three times in 
the neurofeedback phase). 
4. QEEG (approximately 90 minutes, consisted of pre-treatment and post-
treatment records).  
5. MOSES (approximately 5 minutes, baseline consisted five administrations, 
and reassessed five times during the neurofeedback phase). 





assessments three to five times to establish a baseline.  The participant was also 
frequently assessed for emotional distress such as psychotic symptoms or risk of harm to 
self or others using the subscales on the NPQ. 
Phase B 
In phase B, the neurofeedback clinic provided 30-minute neurofeedback LZT 
sessions, four times per week, for approximately 5 weeks.  The neurofeedback clinic 
provided all neurofeedback services separately from the research activities, which were 
the principal investigator’s responsibilities.  The LZT consisted of viewing a computer 
screen with video and audio feedback.  In Figure 6, the participant attempted to create 
more planets in the solar system by meeting the reward threshold for EEG activity.  
 
Figure 6. Brainmaster flash player Brain Planets 
The neurofeedback clinic scheduled ahead for the prospective participant to 
conduct sessions at the same time of day to control for ultradian and circadian effects 





maintain impedance below 10 K ohms (Coben & Padolsky, 2007).   
At the end of each treatment week, the NPQ-LF, CNSVS Neurocognitive Test, 
and MOSES were administered.   After the participant completed 20 sessions of 
neurofeedback training he completed all postmeasures including the CNSVS, NPQ-LF, 
TONI, QEEG, and MOSES.  It required approximately 2 hours for posttesting.  Phase B 
also provided dissemination of findings to the participant and his mother by phone and in 
person.  The participant was asked to provide any subjective reports with a perspective on 
each research question and purpose of the study.  Provisions of additional referrals were 
provided to local community mental health providers.  If the participant had dropped out 
of the study before the 20 sessions then he would have been asked to offer feedback 
regarding early termination and provided any additional referrals if requested to local 
service providers. However, he completed 20 sessions without any adverse events.  He 
was provided mileage reimbursement of 50 cents per mile according to the latest federal 
rate in the IRS Publication 17, Chapter 26.   
Research Questions and Hypotheses 
1. Is neurofeedback LZT related to a change in the core symptoms of autism 
in an adult with ASC? 
H01: μ1 = μ2 –There will be no significant differences in ASC symptoms as 
measured by the Neuropsych Questionnaire, Long Form (NPQ-LF) during the baseline 
and neurofeedback phases in a participant who receives 20 sessions of neurofeedback 





H11: μ1 > μ2 –There will be significant reduction in ASC symptoms as measured 
by the NPQ-LF between the baseline and neurofeedback phases in a participant who 
receives 20 sessions of neurofeedback LZT.    
The analysis consisted of the CDC visual inspection method.  The CDC method 
provides two superimposed criterion lines in the neurofeedback phase to determine an 
effect.  The criterion lines were established by calculating the trend line and baseline 
data’s mean, which was then modified by lowering both lines by .25 standard deviations 
of the baseline data.  According to the binomial test, all five data points in the 
neurofeedback phase must fall below both the CDC trend line and baseline in order to 
show a reliable effect. 
2. Is neurofeedback LZT related to a significant reduction in 
neuropsychological symptoms associated with ADHD, anxiety, depression, and mood 
stability of an adult with ASC? 
H02: μ1, μ2, μ3, μ4 = μ6 , μ7, μ8, μ9  –There will be no significant differences in 
ADHD, Anxiety, Depression, and Mood Stability indices as measured by the NPQ-LF 
during the baseline and neurofeedback phases in a participant who receives 20 sessions of 
neurofeedback LZT.   
H12: μ1, μ2, μ3, μ4 > μ6 , μ7, μ8, μ9 –There will be significant reduction in ADHD, 
Anxiety, Depression, and Mood Stability indices as measured by the NPQ-LF between 
the baseline and neurofeedback phases in a participant who receives 20 sessions of 
neurofeedback LZT.  
The analysis consisted of the CDC visual inspection method.  The CDC method 





effect.  The criterion lines were established by calculating the trend line and baseline 
data’s mean, which was then modified by lowering both lines by .25 standard deviations 
of the baseline data.  According to the binomial test, all five data points in the 
neurofeedback phase must fall below both the CDC trend line and baseline in order to 
show a reliable effect. 
3. Is neurofeedback LZT related to a significant improvement in 
neurocognitive abilities in executive functioning and processing speed in an adult 
with ASC? 
H03: μ1, μ2 = μ1, μ2 –There will be no significant differences in executive 
functioning and processing speed as measured by the CNS Vital Signs (CNSVS) 
Neurocognitive Test during the baseline and neurofeedback phases in a participant who 
receives 20 sessions of neurofeedback LZT.   
H13: μ1, μ2 < μ1, μ2 –There will be significant increase in executive functioning 
and processing speed as measured by the CNSVS Neurocognitive Test between the 
baseline and neurofeedback phases in a participant who receives 20 sessions of 
neurofeedback LZT.     
The analysis consisted of the CDC visual inspection method.  The CDC method 
provides two superimposed criterion lines in the neurofeedback phase to determine an 
effect.  The criterion lines were established by calculating the trend line and baseline 
data’s mean, which is then modified by raising both lines by .25 standard deviations of 
the baseline data.  According to the binomial test, all five data points in the 
neurofeedback phase must fall above both the CDC trend line and baseline in order to 





4. Is neurofeedback LZT related to significant overall improvement in 
nonverbal intelligence in an adult with ASC? 
H04: μ1 = μ2 –There will be no significant difference in general intelligence as 
measured by the TONI between baseline and post-test quotient scores in a participant 
who receives 20 sessions of neurofeedback LZT.   
H14: μ1 < μ2 –There will be a significant increase in general intelligence as 
measured by the TONI from baseline to post-test quotient scores in a participant who 
receives 20 sessions of neurofeedback LZT.   
A simple line graph plotting three baseline and three treatment phase data points 
was used.  A significant change in the TONI was analyzed by visual inspection with an 
observable change in mean performance above the standard error of measurement 
between baseline and treatment phase data points. 
5. Is neurofeedback LZT related to normalization in QEEG measures in an 
adult with ASC? 
 H05: μ1 = μ2 –There will be no significant differences in neurophysiological 
functioning as measured by QEEG based on the ANI DLL and LORETA statistical 
software in a participant who receives 20 sessions of neurofeedback LZT.   
H15: μ1 < μ2 – There will be significant changes in neurophysiological functioning 
as measured by QEEG based on the ANI DLL and LORETA software in a participant 
who receives 20 sessions of neurofeedback LZT.   
QEEG and LORETA maps provided visual inspection of changes in brain 
function toward normalization.  There were also paired-sample t-test analyses that 





were chosen based on the most significant changes and to illustrate main themes of 
findings.  
Variables 
IV – Time (i.e., baseline and neurofeedback sessions) 
DV –Self-reported autism symptoms (i.e., NPQ-LF) 
DV –Self-reported symptoms (i.e., ADHD, Anxiety, Depression, Mood Stability) 
DV – Neurocognitive measures (i.e., executive functioning, processing speed) 
DV – Intelligence measure (i.e., nonverbal IQ) 
DV – Neurophysiological measure (i.e., QEEG difference) 
DV – Adverse effect measure (i.e., psychological and neurological areas) 
Protection of Participant 
The following procedures were followed to protect the rights and best interests of 
the participant: introduction of and discussion of the background of the study, informed 
consent process throughout the study, and disclosures.  Information was provided 
regarding the purpose of the study, the voluntary nature of the study, participant rights to 
confidentiality, the limits of confidentiality, the participant’s ability to discontinue the 
study at any time, and details about the benefits versus risks.  Testing and questionnaires 
are considered minimally invasive.  Nevertheless, the study also provided continued 
monitoring of any potential adverse effects using the MOSES.  The MOSES helped to 
provide an integration of both the principal investigator’s observations and the 
participant’s self-reports, and was used as a continued dialogue of informed consent and 
whether the participant wished to continue the study.  The participant was offered the 





the National Institutes of Health Office of Extramural Research web-based training 
course “Protecting Human Research participants;” certification number 67892.  This 
course provided a basis for the development of the methodology and ethical approach 
toward the development of tools such as the informed consent that is in compliance with 
federal standards.   The Walden Institutional Review Board approved this study 
(Approval number 09-08-11-0072997).   
Summary and Transition 
The purpose of Chapter 4 was to construct the procedures of this study including 
the research questions, hypotheses, recruitment of the participant, data collection, 
measurements, and data analysis.   The neurofeedback clinic was responsible for 
identifying the volunteer participant and providing the neurofeedback, which was 
separate from the proposed research study that included testing and assessment 
procedures only.  The proposal for a single-case design was defended based on the need 
for improved quantitative research methods in neurofeedback and the benefits of 
exploring the effects of it from an idiographic perspective.  Further, the sample size is 
adequate to determine an effect based on the historically large effect sizes found in 
neurofeedback research, number of repeated measures to regularly assess temporal 
change, and broad analysis across various domains of functioning.  Single-case research 
has been a major contributor to the literature on applied behavioral research particularly 





Chapter 4: Results 
Introduction to Results 
 The purpose of this study was to examine the effects of neurofeedback LZT in an 
adult with ASC with neurocognitive and neuropsychological functioning.  This section 
will provide an overview of the sampling method and participant.  The data collection 
and research question analysis will be provided to evaluate each hypothesis and null 
hypothesis.  All the research questions will have data graphed for visual inspection along 
with a review of the results obtained from the study and review of findings. 
Overview of Sampling 
Recruitment 
 A convenience sample was conducted at a local neurofeedback clinic through an 
advertorial and introductory letter (see Appendices A and B), as described in Chapter 3.  
One potential participant was interested in the study but was unable to devote the time 
involved as outlined in the advertorial and letter and so declined participation.   Another 
prospective participant was interested in the study but was being transferred to a facility, 
which was an exclusion criterion.  A third prospective participant met all the criteria for 
the study, agreed with the informed consent materials, and committed to participation in 
the study. 
Sample 
The participant was a 22 year-11 month old right-handed single European 
American male without children and living with his biological parents.  His diagnostic 
formulation consisted of Asperger’s disorder, bipolar disorder, expressive communication 





anxiety disorder not otherwise specified.  Medical concerns consisted of a Chiari 
malformation, a left thalamic mass and static lesion, and partial complex seizures.  He 
had obtained a high school diploma, was able to read all forms, and answered all 
comprehension questions.  He performed in the average range of intelligence, 96 
Nonverbal IQ on the TONI.  During the baseline phase, his depression index scores 
according to the NPQ-LF fell in the moderate range, which was below the cut off for this 
study (i.e., severe range).  He was taking the following medications: Abilify 12.5 mg tabs 
QHS, sertraline HCL 100 mg QAM, and divalproex SOD ER 1750 mg.    
Research Question Analysis 
Research Question 1 
Is neurofeedback LZT related to a change in the core symptoms of autism in an 
adult with ASC? 
H1: μ1 > μ2 –There will be a significant reduction in ASC symptoms as measured 
by the NPQ-LF between the baseline and neurofeedback phases in the participant who 
received 20 sessions of neurofeedback LZT.    
The null hypothesis was rejected. The participant’s reported Asperger’s symptoms 
were significantly reduced between baseline and neurofeedback phase according to the 
CDC method with all five data points in the treatment phase falling below the modified 
linear regression line and mean baseline.  During the baseline phase, the Asperger’s index 
confirmed the participant’s diagnosis of ASC with a self-reported moderate level of 
impairment (M = 171).  During the course of treatment, this index reduced significantly 








































Neuropsych Questionnaire Asperger Index
Conservative Dual Criterion Visual Inspection Chart
Figure 7. Asperger’s index displays a significant improvement. 
Research Question 2 
Is neurofeedback LZT related to a significant reduction in neuropsychological 
symptoms associated with ADHD, anxiety, depression, and mood stability of an adult 
with ASC? 
H2: μ1, μ2, μ3, μ4 > μ6, μ7, μ8, μ9 –There will be a significant reduction in ADHD, 
Anxiety, Depression, and Mood Stability indices as measured by the NPQ-LF between 
the baseline and neurofeedback phases in the participant who received 20 sessions of 
neurofeedback LZT.  
The null hypothesis was rejected.  Figures 8, 9, 10, and 11 indicate a significant 
reduction in ADHD, Anxiety, Depression, and Mood Stability according to the CDC 
method with all five data points in the treatment phase falling below the modified linear 
regression line and mean baseline in all of the measures.  Mood stability fell from 
moderate (M = 197) to mild (M = 128) range, anxiety reduced from moderate (M = 190) 





to mild (M = 108) range, and although ADHD did not change in level of severity, the 



































Neuropsych Questionnaire Asperger Index
Conservative Dual Criterion Visual Inspection Chart
 



































Neuropsych Questionnaire Anxiety Index
Conservative Dual Criterion Visual Inspection Chart
 









































Neuropsych Questionnaire Depression Index
Conservative Dual Criterion Visual Inspection Chart
 




































Neuropsych Questionnaire Mood Stability Index
Conservative Dual Criterion Visual Inspection Chart
 








Research Question 3 
Is neurofeedback LZT related to a significant improvement in neurocognitive 
abilities in executive functioning and processing speed in an adult with ASC? 
H3: μ1, μ2 < μ1, μ2 –There will be a significant increase in executive functioning 
and processing speed as measured by the CNSVS Neurocognitive Test between the 
baseline and neurofeedback phases in the participant who received 20 sessions of 
neurofeedback LZT.     
The null hypothesis was rejected for executive function, but was failed to reject 
the null hypothesis for processing speed.  Figure 12 indicates a significant improvement 
in the CNSVS Executive Function index score according to the CDC method with all five 
data points in the treatment phase above the modified linear regression line and mean 
baseline.  Executive function increased from borderline (M = 76) to low average (M = 88) 



































CNS Vital Signs Executive Function Index
Conservative Dual Criterion Visual Inspection Chart
 






There were, however, no appreciable differences in processing speed as measured 
by the CNSVS Neurocognitive Test between the baseline and neurofeedback phases.  
One of the data points fell below the modified trendline and baseline.  However, there 
was a trend toward improvement and score increased from borderline (M = 79) to low 



































CNS Vital Signs Processing Speed Index
Conservative Dual Criterion Visual Inspection Chart
 
Figure 13. Processing Speed index displays no significant effect. 
There were additional findings not included in the hypotheses that provided 
further evidence of neurocognitive changes associated with executive functioning and 
processing speed.  Cognitive flexibility, complex attention, and reaction time indices 
significantly improved as indicated by the CDC method with all five data points above 








































CNS Vital Signs Cognitive Flexibility Index
Conservative Dual Criterion Visual Inspection Chart
 




































CNS Vital Signs Complex Attention Index
Conservative Dual Criterion Visual Inspection Chart
 







































CNS Vital Signs Reaction Time Index
Conservative Dual Criterion Visual Inspection Chart
 
Figure 16. Reaction Time index displays a significant improvement. 
Research Question 4 
Is neurofeedback LZT related to significant overall improvement in nonverbal 
intelligence in an adult with ASC? 
H4: μ1 < μ2 –There will be a significant increase in general intelligence as 
measured by the TONI-2, TONI-3, and TONI-4 from baseline to intervention phase 
quotient scores in the participant who received 20 sessions of neurofeedback LZT.   
The null hypothesis was rejected. The chart below indicates a significant 
improvement in the TONI IQ.  Visual inspection depicts a significant change in mean 
performance from baseline nonverbal IQ scores (M = 97 NIQ) to treatment phase 
nonverbal IQ scores (M = 108). The change in performance was outside the standard 








































Test of Nonverbal Intelligence
Conservative Dual Criterion Visual Inspection Chart
TONI-3 BTONI-4 ATONI-3 ATONI-2 A TONI-2 B TONI-4 B
 
Figure 17. Nonverbal IQ displays a significant improvement. 
Research Question 5 
Is neurofeedback LZT related to normalization in QEEG measures in an adult 
with ASC? 
H5: μ1 < μ2 – There was significant changes in neurophysiological functioning as 
measured by QEEG based on the ANI DLL and LORETA statistical software in a 
participant who receives 20 sessions of neurofeedback LZT.   
Hypothesis 5 was supported by the data and brain maps. There were changes in 
neurophysiological functioning according to pre and post-EEG recordings. 
Baseline. During baseline, the participant presented with abnormal findings for 
his EEG with regard to absolute and relative power, connectivity, and paroxysmal waves.  
Specifically, he had excess 8 Hz and generally low voltage throughout his EEG record, 
and his peak alpha frequency was 9 Hz.  Although paroxysmal waves were noted, they 
were not interictal or sustained and waves were transient.  For connectivity measures in 






beta bandwidths.  Phase lags existed in delta and theta for eyes closed frontal, temporal, 
and occipital sites.  Amplitude asymmetry is depicted in right frontotemporal alpha and 




Figure 18. Baseline Eyes Closed QEEG Neuroguide connectivity maps. 
 
Visual Inspection of Absolute Power. The following EEG acquisition maps 
were with eyes closed only using a Laplacian montage due to medication effects, which 
provides a reanalysis in difficult to interpret recordings (Rowan & Tolunsky, 2003).  It 
should be noted that the posttreatment assessment was impacted by low-grade muscle 
tension and fatigue because the participant stayed up later than usual to celebrate a 
holiday festivity the prior evening. He denied any alcohol or other substance use.  
Therefore, the posttreatment EEG records should be interpreted with a measure of 
caution.  The EEG recording was edited for artifact to reduce noise by a minimum of 60 





processing to eliminate EEG contamination by eye movement, muscle tension, and 
fatigue in order to obtain a sample of the EEG record representative of the client’s overall 
functioning.  The data exceeded commonly used standards in EEG analyses dictating a 
minimum split-half reliability above .95 and test-retest reliability exceeding .90.   
Figure 19 provides pre and post-QEEG Neuroguide Z scored FFT summaries of 
absolute power maps for each frequency bandwidth.  His posttreatment showed 
significant increases in theta, alpha, and beta power in frontal regions.  This is noticeable 
by gradient shift from dark blue (representing three standard deviations below the norm) 
to light blue-green in the posttreatment maps below.  Movement from blue to green 
represents a shift toward a more normalized and efficient state of cortical function and 






           
 





LORETA Maps Comparison.  In coordination with the neurofeedback clinic 
consultants, I examined frequency ranges between 1-40 Hz.  They identified voxels 
indicative of significant change relevant to this study.  Specifically, changes in beta 
frequency band were noted, and 18 Hz was chosen to depict normalization in the EEG.  
Each slide provides the Cartesian vector fields with coordinates on the x, y, and z axes 
depicting slices of a generic brain.  Figure 20 provides the pretreatment in the top row 
and posttreatment in the bottom row.  Each row consists of three individual maps 
consisting of the horizontal, sagittal, and coronal views of the brain respectively.  The 
darker the gradient blue the more indicative of lowered absolute power in beta 18 Hz 
(i.e., abnormal brain function), whereas the areas with the light blue or no color signifies 
areas of normalized brain function.  Figure 20 shows significant EEG normalization with 
the apparent gradient shifts from darker blue to lighter blue or no color in posttreatment 
LORETA.  There is noticeable improvement particularly in the frontal, temporal, and 
parietal areas of the brain (i.e., Brodmann areas 21, 6, 17 and 18).  Overall, the pre and 
posttreatment LORETA provide additional evidence of normalization in beta frequency, 
which further supports improvement in higher cognitive processing abilities like 


















Side Effect Scales 
 
 The MOSES provided monitoring of side effects. The client indicated no change 
in neurological side effects symptoms. There was improvement in the psychological side 









































Monitoring of Side Effects Scale
Conservative Dual Criterion Visual Inspection Chart
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Monitoring of Side Effects Scale
Conservative Dual Criterion Visual Inspection Chart
 






 Tables 2, 3, 4, and 5 summarize the findings in self-report, neurocognitive, and 
side effect measures.  Each table consists of the mean percentage change between 
baseline and treatment phases.  
Table 2 
Mean Change for Self-Reports 
Dependent Variables Baseline M Treatment M % Change 
Asperger’s NPQ Index 171 129* 25% 
ADHD NPQ Index 233 164* 30% 
Anxiety NPQ Index 190 128* 33% 
Mood Stability NPQ Index 197 128* 35% 







*Statistically significant improvement by the Conservative Dual Criterion. 
 
Table 3 
Mean Change for Neurocognitive Abilities 
Dependent Variables Baseline M Treatement M % Change  
Processing Speed CNSVS 79 84 6% 
Executive Function CNSVS 76 88* 16% 
Cognitive Flexibility CNSVS 74 87* 18% 
Reaction Time CNSVS 67 80* 19% 
Complex Attention CNSVS 78 96* 23% 
 
 







Mean Change for Intelligence 
Dependent Variables Baseline M Treatement M % Change  
TONI 97 108* 12% 
 
 
*Statistically significant improvement by the Conservative Dual Criterion and visual inspection methods. 
 
Table 5 
Mean Change for Side Effects 
Dependent Variables Baseline M Treatment M % Change 
Neurological MOSES 14 14 0% 






*Statistically significant improvement by the Conservative Dual Criterion. 
Conclusion 
 This concludes Chapter 4 results section.  The results are consistent with 
previously published research on neurofeedback in autism.  Specifically, this provides 
evidence that the participant benefitted from neurofeedback LZT with improved 
neuropsychological symptoms, neurocognitive abilities, intelligence, and neurological 
processes as measured by QEEG and LORETA maps.  Further, neurofeedback depicted a 
favorable side effect profile with no changes in neurological adverse effects and 





Chapter 5: Discussion 
Introduction to Discussion 
Over 25 years ago, autism was considered a rare condition with a prevalence rate 
of 1 in 2,000 children (CDC, 2007).  However, in recent years, there has been an 
exponential growth in the prevalence rate with 1 in 110 children being diagnosed with 
some form of autism (CDC, 2009).  The cost of services to treat ASC may be as high as 
$43,000 per year, yet historically ASC research and interventions have been significantly 
underfunded compared to other developmental disabilities (Ganz, 2006).  In addition to 
the core symptoms, autism is often comorbid with other psychiatric disorders such as 
anxiety, depression, ADHD, and bipolar disorders (Bellini, 2006; Raja & Azzoni, 2008; 
Shtayermman, 2008; Volkmar & Klin, 2005).   Such comorbidity is also implicated by 
ASC’s research on pathophysiological processes of ASC in exorphins, serotonergic, 
dopaminergic, and hypothalamic-pituitary-adrenal systems (Anderson & Hoshino, 2005).  
Specifically, hyperserotonemia in ASC has been thoroughly researched in ASC (Schain 
& Freedman, 1961), and may explain the development of mood disorders in autism.  The 
complexity of the disorder often warrants a multimodal intervention approach to 
maximize functioning especially in adulthood where issues such as employment, 
independent living, and self-sufficiency are critical.  However, a vast majority of research 
in autism has been focused on treating children (Coben et al., 2010; Roy et al., 2009; 
Wolf & Paterson, 2010).  This study provides vitally needed exploration into the area of 
ASC within adults, as well as to evaluate the effect of neurofeedback LZT in a 






Summary of Research Findings 
The participant met the study’s criteria and was reflective of the complex 
neuropsychological issues reported in the literature review.   He has a diagnostic history 
of Asperger’s disorder, bipolar disorder, expressive communication disorder (i.e., apraxic 
speech), impulse control disorder not otherwise specified, and anxiety disorder not 
otherwise specified, which are congruent with research on comorbidities in ASC (Bellini, 
2006; Raja & Azzoni, 2008; Shtayermman, 2008; Volkmar & Klin, 2005).  Further, he 
also has neurological issues associated with a Chiari malformation, left thalamic mass 
and partial complex seizures.  He presented with impaired gross motor coordination and 
abnormal QEEG measures in posterior regions, which may be associated with the Chiari 
malformation, a neurological defect in the cerebellum and brainstem affecting balance 
and coordination (National Institute of Neurological Disorders and Stroke, 2011).  The 
left thalamic mass and static lesion may also have played a role in the significantly low 
amplitude relative and absolute powers shown in the QEEG because the thalamocortical 
connection is a critical pacemaker for EEG activity on the cortex (Hughes & Roy, 1999; 
Thompson & Thompson, 2003; Townsend, 2007).  Further, there are high rates of 
neurologic conditions like seizure disorders and EEG paroxysmal discharges in ASC 
(Coben & McKeon, 2009; Kagan-Kushnir et al., 2005), and this participant had a history 
of partial complex seizure disorder and EEG paroxysmal discharges.  Overall, he 
presented with a complex neuropsychological profile typical of individuals with ASC in 
research. 
Despite the complexity of this participant neurofeedback LZT resulted in overall 





objective measures.  The participant reported significant improvement in Asperger’s 
symptoms and other symptoms associated with ADHD, mood stability, depression, and 
anxiety.  He also reported significant reduction in Asperger’s symptoms from a moderate 
to a mild level of severity as assessed by the NPQ-LF.  Coben and Padolsky (2007) 
indicated that there was a 40% improvement in ASC symptoms in their sample of 
children with ASC in comparison to the present study that found a 25% improvement in 
those symptoms. For this study, the participant’s ASC symptoms stabilized and showed 
little change over the treatment phase, which may suggest a limited treatment effect and 
the need for additional neurofeedback sessions.  Further, he reported significant 
improvement in the NPQ-LF psychological indices with an average reduction of 
symptoms in ADHD by 30%, Mood Stability by 33%, Anxiety by 35%, and Depression 
by 41%.  The participant had been diagnosed with significant symptoms in these areas, 
and neurofeedback appeared to lead to a favorable response on his related psychological 
symptoms.  Hammond (2005) explored neurofeedback research in treating depression 
and found that there is a signature frontal asymmetry alpha, which was similar to our 
participant’s QEEG frontal asymmetry.  It is interesting to note that the most significant 
reduction was reported in depressive symptoms, and this may suggest that the targeted 
sites in the frontal lobe were responsible for the significant improvement, because 
neurofeedback training in the frontal lobe has been found to reduce depression 
(Hammond, 2005).   
Consistent with past research on neurofeedback (Berman et al., 2005; Thompson 
et al., 2010), the participant gained in nonverbal intelligence score from baseline to 





reaction time significantly improved from baseline to intervention phase, which are 
consistent with his self-reported ADHD, anxiety, depression, and mood stability.  This 
further supports both the overall intellectual improvement that is dependent on executive 
functioning.  Other researchers have found improvement in neurocognitive measures like 
Stroop, ToLDX, and TOVA tests after neurofeedback interventions (Berman et al., 2005; 
Knezevic et al., 2009, 2010; Pineda et al., 2008).  There are theories that might suggest 
the reason for such improvement especially with the participant’s training protocol, 
which included fronto-temporal sites.  For instance, frontal lobe deficits particularly with 
executive functioning, weak central coherence, and TOM and empathy are critical issues 
for treatment and might offset abnormal development found in the frontal lobe (Minshew 
et al., 2005; Thompson et al., 2010a).  Furthermore, areas such as the pars opercularis 
within Broca’s area influences mirror neuron activity and social interconnectedness and 
other areas along the prefrontal cortex and temporal lobes (Coben, 2009b; Iacoboni & 
Dapretto, 2006; Vollm et al., 2006).  In this study, processing speed was not significantly 
impacted by neurofeedback, which might be the result of the site locations used in the 
neurofeedback training.  Specifically, the training did not consist of parietal and occipital 
lobe sites which are linked to with processing speed in research (Peers et al., 2005).  
However, the chart did show gradual improvement over the 20 sessions, which suggests 
further training may have resulted in significant improvement. 
Similar to this participant, past research has found that ASC is associated with 
right hemispheric asymmetry and hypercoherence particularly in the frontal lobe, which 
suggests anxiety and social motivation issues in ASC (Coben, 2009a; Coben & Myers, 





paroxysmal discharges, which were noted within the record and consistent with past 
research (Coben & McKeon, 2009; Kagan-Kushnir et al., 2005).  He had excess 8 Hz and 
generally low voltage throughout his EEG record.  For the resulting changes of pre and 
posttreatment maps, the findings were interpreted with caution because of low grade 
muscle tension, medication effects, and fatigue during the posttreatment EEG acquisition. 
To counteract these variables, the EEG recording was edited for muscle artifact, included 
only eyes closed condition to reduce noise, and Laplacian montage to cancel out 
medication effects.  Overall, posttreatment QEEG and LORETA maps showed increased 
EEG power across bandwidths particularly in the frontal and temporal lobes. Specifically, 
Brodmann areas 21, 6, 17, and 18 had significantly increased beta power, which is 
important for higher information processing such as executive functioning.  Increasing 
power was the primary need for neurofeedback training to enhance brain function.    
Finally, as with past research on neurofeedback (Coben & Padolsky, 2007), no 
significant adverse effects were reported by the participant, and associated with general 
improvement in neuropsychological symptoms.  With regard to potential side effects, I 
purposely utilized a multimodal assessment strategy to evaluate neuropsychological 
measures and neurophysiological measures to identify the most effective neurofeedback 
protocol, which is the recommended standard of practice (Hammond & Kirk, 2008).  This 
hoped to offset potential risks of training associated with changing brain function such as 
seizures, fatigue, or agitation.  The participant’s side effect profile revealed reduced 
psychological side effects when measured by the MOSES, a commonly used side effect 
measure for individuals with developmental disabilities.  His neurological side effect 





no adverse incidents such as an increase in extrapyramidal symptoms or seizures.  This is 
reflective of past research finding a high benefit to risk ratio compared to other 
procedures like psychotropic medication and no abreactions particularly with 
neurofeedback approaches like bipolar montage and LZT (Coben & Padolsky, 2007; 
Collura et al., 2010).  Neurofeedback might actually reduce psychological side effects 
(e.g., agitation, anxiety) more expediently, while neurological side effects might require a 
longer course of training.   
Overall, these results suggest that neurofeedback might be helpful in mitigating 
and stabilizing symptoms associated with adulthood ASC and that longer-term training is 
indicated due to the developed neural networks.  However, research in neuroplasticity has 
suggested that neurodevelopment continues throughout adulthood with methods that 
challenge neurocognition (Beauregard & Lévesque, 2006; Jones, 2004; Malkowicz & 
Martinez, 2009; Pinel, 2008).  Neurofeedback research has evidence of neuroplasticity 
indicated by normalizing the neural pathways based on changes in EEG activity and 
neuroimaging (Lévesque, Beauregard, & Mensour, 2006; Malkowicz & Martinez, 2009).  
Although long-term effects of neurofeedback were not explored in this study, there has 
been research that supports maintained treatment effects in children with ASC up to a 
year, which is indicative of neuroplasticity and lasting changes in brain function (Coben, 
2009a; Kouijzer et al., 2009a). 
Limitations of the Study 
 The limitations of this study consist of the specificity of the population and 
research question, limited generalizability due to the sample size of one, practice effects, 





sample of one participant consisted of a European American male, which limits the 
generalization to this individual.  As noted, ASC is a heterogeneous diagnosis, and the 
multiple comorbid diagnoses present in this individual demonstrate that heterogeneity.  
Sampling issues and randomized controlled research have been historically a problem for 
neurofeedback research (Rojas & Chan, 2005).  The present study was purposefully a 
single-case research design, which did not allow for a larger sample or randomized 
assignment of participants.  However, by electing to conduct a single subject design, the 
participant was able to act as his own control with a baseline and intervention phase.  The 
visual inspection aspect of the methodology might be questionable when compared to 
more stringent approaches such statistical procedures and subjective reports by the 
participant (Kazdin, 1982).  The participant, by being involved in the baseline measures, 
might be predisposed to report greater concerns initially, but in the intervention phase 
report decreased symptoms because of being involved in the study and expectations of 
change or simply as an effect of regression to the mean.  However, the results of self-
report measures were compared against results of ability measures that are not subjective 
in nature.  The participant’s exposure to repeated measures may also lead to practice 
effects over time and to improvement in those measures (Kazdin, 1982).  An additional 
limitation is that the participant had multiple mental health conditions, which is common 
in ASC, but makes it difficult to isolate the effects of neurofeedback in relation to ASC.  
Lastly, the principal investigator is biased having researched neurofeedback and acquired 
a Biofeedback Certification in Neurofeedback with strong opinions about the 
effectiveness of neurofeedback treatment.  This bias may have influenced subjective 






This research adds to the literature of technologically advanced 
neuropsychological interventions for adulthood ASC. This is the first quantitative study 
that evaluated neurofeedback LZT in an adult with autism using a multiple baseline 
single-case research approach.  Currently, the research in the field is lacking in 
investigations of the efficacy of neurofeedback in adulthood (Coben et al., 2010).  For 
adulthood ASC, treatment efficacy research has historically been lacking as with 
psychosocial rehabilitation and psychotherapy (Roy et al., 2009; Shea & Masibov, 2005; 
Wolf & Paterson, 2010).  Knezevic, Thompson, and Thompson (2009, 2010) found that 
age or intellectual functioning did not show any significant differences in the level of 
improvement by neurofeedback.  This suggests that neurofeedback may have equal 
benefit in adulthood as it does in childhood in individuals with ASC.   
Furthermore, single-case research in neurofeedback has mainly consisted of 
qualitative approaches with subjective or interpretive reports that do not provide 
quantitative changes in pre and posttest measures (Beaumont & Montgomery, 2005; 
Collura et al., 2010; Othmer, 2007; Rutter, 2009; Sichel, Fehmi, & Goldstein, 1995; 
Thompson & Thompson, 2003a, 2003b).  There are few studies published with 
quantitative experimental formats and single-case investigations such as AB designs in 
adults with ASC (Blampied, Blampied, Barabasz, & Barabasz, 1996; Kazdin, 1982).  The 
current study results demonstrate a further need to explore this treatment in a larger 
sample of adults with ASC.  It provides clear evidence of neurofeedback LZT’s effect on 
neuropsychological symptoms and neurocognitive performance in one adult with ASC.  





Implications for Social Change 
 The results of this study may be used to advance social change by helping adults 
with ASC to improve their overall quality of life through neurofeedback: an empirically 
supported intervention for treating autism.  By providing evidence that neurofeedback is 
beneficial in multiple symptoms domains it may also help providers to implement or 
suggest neurofeedback as an adjunct treatment.  These findings advance research in 
neurofeedback on neuropsychological functioning in ASC, and provide support for the 
use of interventions in adults with ASC.  The findings indicate the possibility of 
neuroplasticity through neurofeedback LZT in improving neurocognitive abilities, 
reduction of neuropsychological symptoms, and improved neurophysiological 
functioning.  Research on neurofeedback in individuals with ASC has largely focused on 
children and adolescents rather than adults (Roy et al., 2009; Wolf & Paterson, 2010).  
Autism is considered a developmental disorder with continuous delays in social-
communication and problems related to obsessive interests or repetitive behaviors (APA, 
2000).   Later in life, adults with ASC have problems across various psychosocial 
domains, which lead to further psychological symptoms related to anxiety and mood 
disorders (Shea & Masibov, 2005).  This study provides support for the use of 
neurofeedback in improving overall functioning including measures of psychological 
symptoms, neurocognitive and intellectual abilities, and neurophysiological processes 
into adulthood.   
This research may also advance social change by encouraging more research in 
rural areas because the context of this study was in northwestern Michigan, a rural area 





of Agriculture, Economic Research Service (2000), Michigan is a predominantly rural 
state with around 66% of Michigan being rural along with 15% of households being 
impoverished.  Rural areas are especially challenging for access to care and services for 
individuals with ASC.  Problems with limited resources, a 30-40 mile drive to the closest 
provider, and a waiting list for specialists extending several months are common (Hutton 
& Carron, 2005).  In addition, rural areas present many challenges for professionals and 
primary care providers in addressing and coordinating referrals to the multiple specialty 
services that are needed for individuals with ASC and their families (Symon, 2001).  
Rural poverty also has led to poorer health, less education, and other problems associated 
with decreased agriculture and profitability in rural communities (Judd et al., 2002).  
These are issues that are indicated in the backdrop of this study, which further advocates 
for research and better access to care in rural areas.     
Implications for Future Research and Practice 
 The need for technologically advanced interventions in ASC is critical 
particularly in adulthood.  Given that ASC is a lifelong condition; it will require more 
research to validate empirically interventions that work.  Ongoing research in adulthood 
ASC will be important in guiding clinical practice toward improving and promoting 
overall wellbeing in adults with ASC.  This is the first neurofeedback LZT study for an 
adult with ASC providing psychometric and neurophysiological findings supporting its 
effect.  However, further research is needed in larger samples and additional single-case 
research design.  This study could be replicated to determine if effects are consistent for 
other participants.  Ninety percent of behavioral interventions for ASC have been single-





approaches for ASC (Matson, Matson, & Rivet, 2007; Smith, 2008). It is encouraged that 
outpatient clinic settings employing neurofeedback in their practice use single-case 
research designs (Blampied, Barabasz, & Barabasz, 1996; Kazdin, 1982).   
 An unintended finding and important issue for future neurofeedback research in 
adults with ASC is the need to have accurate pre and post-EEG acquisition due to the 
various neuropsychological complications with this population.  For instance, it is likely 
due to high comorbidities with other disorders that most adults with ASC will have some 
form of psychopharmacological or neurological interventions such as a mood stabilizer, 
vagal nerve stimulator, or anticonvulsant medication.  This will impact the findings of 
QEEG and LORETA imaging.  Also, participants with ASC have repetitive behaviors 
and stereotypies that make it difficult to edit and prevent artifacts.  This participant 
represented a typical adult with ASC who had difficulties in a wide range of areas, 
medications to address neuropsychological complexities, and artifacts that impacted the 
pre and post-EEG records.  Consideration might be made ahead of time for multiple 
baseline and post-EEG recordings to average pre and posttreatment to improve 
consistency of findings. 
Conclusion 
This study found that an adult with ASC benefited from 20 sessions of 
neurofeedback LZT following a comprehensive evaluation of both neuropsychological 
functioning and neurophysiological processes.  The single-case research design offered a 
unique ability to evaluate the trend of data points between a control phase and treatment 
phase on a number of neuropsychological, neurocognitivie, and psychological variables. 





which included psychological symptoms, neurocognitive abilities, intelligence, and 
neurophysiological functioning.  The consistency in these results allowed for validation 
by both objective and subjective measures that neurofeedback LZT was effective in this 
adult with ASC.  These findings provide evidence that neurofeedback LZT may be 
beneficial in improving developmental deficits into adulthood.  Future research is needed 
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Wave  Frequency Brief Description & 1 Epoch Picture 
Delta 1-4 Hz Function: Sleep, rest, drowsy states, or problem solving. 
Morphology: Rhythmic or arrhythmic. 
Disorder: TBI or stroke- focal, ADHD, ASC, or LD- widespread.  
 
Theta 4-8 Hz Function: Spacey, working memory, deep states, insight, creativity. 
Morphology: Square top or sinusoidal rhythm rhythmic or arrhythmic. 








Function: Alertness, readiness, meditation-relaxed, not processing. 
Morphology: Sinusoidal wave; mu rhythms.  
Disorder: Depression-high amplitude in anterior cortex; ADD, ASC. 
 
SMR 12-15 Hz Function: Internally oriented, mental alertness, relaxation- C3, Cz, C4.  
Morphology: Similar to Beta 1. 











Function: Processing, analytic, externally oriented, focus, attention.  
Morphology: Rhythmic activity. 
Disorder: OCD, sleep disorders, LD, anxiety, depression, ASC. 
 
Gamma 30-50 Hz Function: Cognitive processing, learning, problem solving tasks.   
Morphology: Synchronous bursts. 




Note: Information compiled from Demos, 2005; Thompson & Thompson, 2003; Townsend, 2007; 






Thank you for considering this research project.  A client with autism who is considering 
neurofeedback at Great Lakes is invited to participate in this study, which will include 5 
assessments over the course of 1-2 months.  Mr. Lucido, principal investigator, is seeking 
an adult-18 years or older, who has been diagnosed with autism spectrum disorder, 
pervasive developmental disorder, or Asperger’s syndrome.  If you are pregnant, older 
than the age of 65, have intellectual disability, diagnosed with Rett’s disorder, non-
English speaking, taking more than three medications, or in a facility, then you will be 
unable to qualify for the study.  This research study will explore the impact of your 
regularly scheduled neurofeedback sessions with Great Lakes.  The research study itself 
will involve only the assessment that will take place before, during, and after your 
neurofeedback at the clinic.  The participant will need to be able to understand and 
independently consent to participation in the study, and complete a series of evaluations 
that will take at least 6-8 sessions with 1-2 hours of testing at each session.   
To find out more about the study, please contact Michael Lucido, principal 
investigator (phone #).  Mr. Lucido is conducting this research as a part of his doctoral 
program at Walden University.  Dr. Lisa Scharff will be the Committee Chair, and 
overseeing the project.  He is presently also an internship student with North Country 
Community Mental Health.  If you are related or presently working with Mr. Lucido, you 
are ineligible for the study.  He will submit informed consent information, additional 
background information, and contact information for consideration with participating in 






RESEARCH STUDY SEEKING AN ADULT CLIENT WITH AUTISM 
SPECTRUM CONDITION TO PARTICIPATE IN AN INTERVIEW, TESTING, 
AND ASSESSMENTS WHILE THEY ARE RECEIVING NEUROFEEDBACK.  
This study will include an interview, testing, and assessments that will measure changes 
while you are receiving neurofeedback by  Great Lakes. If you are pregnant, older than 
the age of 65, have an intellectual disability, diagnosed with Rett’s disorder, non-English 
speaking, taking more than three medications, or in a facility, then you will be unable to 
qualify for the study. One individual will be selected and will need to be able to read and 
provide consent to completing interview, testing, and assessments involved in the study.  
CONSENT FOR THIS STUDY ONLY INCLUDES CONSENT FOR THE 
INTERVIEW, TESTING, AND ASSESSMENTS CONDUCTED BY THE 
INVESTIGATOR FOR ANALYSES.  It requires attendance for 6-8 sessions for 4-6 
weeks.  To find out more please contact:  
Michael Lucido at (phone #).  He is a conducting this research as a part of his 
doctoral program at Walden University.   If you are related or presently working with Mr. 







Introduction to the Study 
Prospective clients of Neurotherapy who have been diagnosed with autism are invited to 
participate in this study.  This study will consist of an ongoing evaluation, which includes 
an interview, testing, and assessments.  The consent is only for these procedures.  
Consent for neurofeedback is completely separate and through Neurotherapy alone.  You 
are invited to voluntarily participate because you have a diagnosis of autism and meet the 
requirements of the study (English speaking, average intelligence, between 18-64 years 
old, and currently taking less than three medications).   
Research Approach  
The research will consist of interviews, assessments, and testing that take place during 
the process of receiving neurofeedback.  Participants would be asked to complete 6-8 
sessions that include 5 assessment procedures for a total of 4-6 weeks while they are 
doing regularly spaced neurofeedback sessions.  The interview, assessments and testing 
are components of the research study, the neurofeedback is not.  Self-reports will consist 
of questions related to symptoms of autism, depression, anxiety, mood, attention, and 
impulsivity.  The tests will measure a part of intelligence, mental flexibility, and speed. 
Why is this research being done? 
The present study is important for finding out if there are any changes in the assessments 
and testing during neurofeedback in an adult with autism.  It will also complete a part of 






How many people will take part in this research study? 
There will be one participant for this study.   
How long will you take part in this research study?  
There will be 1-2 hours for each meeting and at least 6 meetings over 4-6 weeks.   
What do we do if we can be in this study?  
Contact the Michael Lucido to schedule a meeting. 
What will happen to the results of the study?  
Your results (any changes in the testing material from the first testing to the second 
testing) will be given to you in the final meeting in a one page summary. All the 
information will be kept within a password protected computer.  No information such as 
names or addresses will be kept after all of the information is collected. 
Is there a payment with being involved? 
There is no payment for participating in this research.  However, for being involved, 
traveling costs will be provided at the current Federal government mileage rate. 
Volunteering: 
Being involved in the study is completely voluntary, which means everyone will respect 
your decision of whether or not you want to be in the study. No one will treat you 
differently if you decide not to be in the study. If you decide to join the study now, you 
can still change your mind during the study and stop participating. If you feel stressed 
during the study you may stop at any time. You may skip any questions that you feel are 
too personal. 
Researcher Disclosure: 





Privacy and Confidentiality Procedures: 
When results of the study are reported in meetings and journals, no one will be given any 
information that could identify the individual enrolled in the study such as names. 
Michael Lucido will not release any information about your research involvement 
without your written consent.  
Benefits Being in the Study: 
The primary benefit is to help research in autism.  No one knows if neurofeedback is 
related to changes in brain functioning in adults with autism.  Articles are available upon 
request about neurofeedback. 
Possible Side Effects:  
The main side effect for the study is fatigue during the tests and personal questions.  
Also, this study includes a detailed evaluation and approach that has been used in many 
neurofeedback studies.  Regardless, participants will be closely monitored for potential 
side effects during the assessments and testing meetings. 
 I have read and can understand the above information.  
 I understand that this study only includes testing and assessment procedures while 
I am receiving my neurofeedback through Neurotherapy. 
 I give my consent voluntarily and I was not forced to enter this study. 
 I am willing to participate in this research study. 
 I understand that my name and other information will not be released and that I 
will be assigned a number to protect my confidentiality. 
 I am willing to sign a release to allow Michael Lucido to contact my current or 





 I was not told to go into this study by a referral from a clinic for treatment. 
 I am not a family member of Michael Lucido.   
 I am not in therapy with Michael Lucido.   
 I understand if I drop out of the study I will not be prevented from ongoing 
treatment at Neurotherapy for services. 
 I understand that I may stop the research study at any time without any penalty or 
problems for future services. 
 I understand that testing and assessments are not intended to diagnose disorders. 
 I am consenting to participate in interviews, testing, and assessments. 
 I understand that there may be no effect at all from participating in the research. 
 I understand that there may be discomfort in completing the interviews, testing, 
and assessments including the time involved.   
 I understand that involvement in this research will include 5 assessment 
procedures over the course of 4-6 weeks for a total of 1-2 hours per session.   
 If I am in crisis, I will be offered an immediate referral for services at the local 
emergency room or community mental health. Also, I will be provided the crisis 
phone number: (800) 442-7315 at the Third Level Crisis Center in Traverse City.   
 I understand that my testing and assessment data may be reviewed with a mentor, 
therapist, and/or doctor on a consulting basis. 
 I understand that my research records are private to the fullest extent of the law, 
except in cases of state and federal laws that mandate mental health providers to 





 If I have concerns about how my participation might impact my wellbeing, I will 
consult my doctor prior to my participation in the research study. 
 I will disclose a list and changes of my medications or vitamins/supplements 
throughout the course of this study and talk with my doctor regarding any 
concerns.  
 I understand that I will be able to continue neurofeedback treatment through 
Neurotherapy following the study and that it will not impact my treatment.   
 I accept that I have been offered time to ask questions regarding all the 
information above and that these questions have been answered to my liking. 
Canceling Appointments and Stopping the Study:  
Please call 24 hours to reschedule any appointment.  
You may stop the research study at any time for any reason. As a courtesy, please feel 
free to call or write a note about what led you to stop.  
Contact information: 
You may ask any questions you have now. Or if you have questions later, you may 
contact the researcher via researcher’s phone at (phone #) or email address at 
michael.lucido@waldenu.edu.  If you want to talk privately about your rights as a 
participant, you can call Dr. Leilani Endicott. She is the Walden University representative 
who can discuss this with you. Her phone number is 1-800-925-3368, extension 1210. 
Walden University’s approval number for this study is 09-08-11-0072997 and it expires 







Consent to Participate in Study: 
 
Signature participant code       DATE 
 
Advocate witness (e.g., family member, therapist, doctor)   DATE 




Comprehension Check for Informed consent 
Do you understand that the purpose of the research sessions is not to help you, but rather 
to learn if there are any changes testing and assessments? 
What will you are doing in this study? 
Tell me what you are agreeing to do for the study? 
Can you stop at any time? 
How long will this study be and the length of each session? 
Do you know how the research report will be able to protect your identity? 
Do you understand that we might learn that there will be no changes during the study? 







Name of Signer:        
During the course of my activity in collecting data for this research: “The Effect of 
Neurofeedback Live Z Score Training on Neuropsychological Functioning in Adults 
with Autism Spectrum Disorder: A Single-Case Research Design” I will have access 
to information, which is confidential and should not be disclosed. I acknowledge that 
the information must remain confidential, and that improper disclosure of confidential 
information can be damaging to the participant.  
By signing this Confidentiality Agreement I acknowledge and agree that: 
1. I will not disclose or discuss any confidential information with others, including 
friends or family. 
2. I will not in any way divulge, copy, release, sell, loan, alter or destroy any 
confidential information except as properly authorized. 
3. I will not discuss confidential information where others can overhear the 
conversation. I understand that it is not acceptable to discuss confidential information 
even if the participant’s name is not used. 
4. I will not make any unauthorized transmissions, inquiries, modification or purging of 
confidential information. 
5. I agree that my obligations under this agreement will continue after termination of 
the job that I will perform. 





7. I will only access or use systems or devices I’m officially authorized to access and I 
will not demonstrate the operation or function of systems or devices to unauthorized 
individuals. 
Signing this document, I acknowledge that I have read the agreement and I agree to 
comply with all the terms and conditions stated above. 
 
______________________________________________________________________ 






Research Volunteer Registration and Screening Form 
Last Name_________________First Name_________________Middle Initial_______ 
Address:_______________________________________________________________ 
City: _______________State:__________________ZipCode:____________________ 
Phone:______________________Work Phone:______________Cell Phone:________ 
Birth Date:______________Gender (M/F):______Marital Status:_______Pregnant:____ 
Race/Ethnicity: 
___American Indian/Alaskan Native ___Asian ___Black/African American 
___Native Hawaiian/Pacific Islander ___White ___Other 
Current Living Arrangement (Check all that apply) 
___Alone ___Mother ___Father ___Sibling(s) ___Relatives/Kin 
___Guardian ___Spouse ___Partner/Significant Other ___Child(ren) 
___Foster Children ___Unrelated persons 
Years of Education_____ Occupation______________________________________ 
Previous Mental Health Services (Y-Yes N-No) 
___Inpatient Care ___Partial Care ___Other 24-Hour Care ___Outpatient 
May we contact you (Y-Yes N-No) 
___Call at Home? ___Call at Work?___Message at Home?___Message at work?___Mail 
Information? 
Emergency Contact: ______________________________________________________ 






Have you or a family member been diagnosed with a developmental disability, autism 
spectrum disorder, speech or language delay, obsessive-compulsive disorder, or learning 
disability?_______________________________________________________________ 
Are you diagnosed with Rett’s Disorder:  YES NO 
If you were diagnosed, please indicate what age you were first diagnosed with autism or a 
developmental disability: ___________________________________________________ 
Are you currently taking any medications? If yes, please specify: __________________ 
________________________________________________________________________ 
________________________________________________________________________ 
Do you have a guardian?  YES NO 
Can you read a newspaper or magazine? YES NO 






Authorization to Disclose PHI for Research Purposes 
A copy of the form will be given to the research participant for his/her personal records. 
Research Participant Name: ______________________________________________ 
Phone:_______________Address:____________________________________________ 
Discloser of Information: _______________________________________________ 
Recipient of Information: Michael Lucido, Principal Investigator 
Means of disclosing information (i.e., verbal, written, etc.): Verbal or written. 
Information to be disclosed: Confirmation that this individual has an autism spectrum 
condition-pervasive developmental disorder, Asperger’s syndrome, or autistic disorder. 
Reason for the Release: Released/obtained for the purpose of research. 
Authorization Provided by Research Participant:  
I understand that this authorization permits the release of information between the two 
parties named above. 
I understand that I have the right to refuse to sign this release form. 
I understand that upon release, this information will be kept confidential; my identity will 
be concealed and data will not be disclosed outside of the specified individuals/agencies. 
I understand a photocopy of this release will be as effective as the original. 
I understand this authorization will be in effect for 1 month from the date signed unless 
cancelled by me in writing. 
________________________________________________________________________ 
Signature        DATE 
________________________________________________________________________ 






Neuropsych Questionnaire-Long Form Subscales 
Asperger/Autism Questions 0 1 2 3 
1 Avoiding eye contact      
2 Difficulty developing friendships     
3 Difficulty understanding sarcasm, metaphors or jokes     
4 Hard to relate to other people     
5 I can't relate to other people, socially or emotionally     
6 I don't attend to social signals     
7 I don't respond to other people's expressions or body language     
8 Not able to begin or to sustain a conversation with other people     
9 Not responsive to other people's feelings     
10 Odd preoccupations or interests     
11 Preoccupied by a particular interest to the exclusion of other things     
12 Rigid, inflexible, resistant to change     
13 Strongly attached to routines or sameness in the environment     
14 I can't feel close to another person     
15 Withdrawn, isolated     
Depression Questions 0 1 2 3 
1 Crying spells     
2 Feeling depressed     
3 Feeling discouraged about the future     
4 Feeling empty inside     
5 Feeling hopeless     
6 Feeling irritable     
7 Feeling little or no interest in things     
8 Feeling lonely     
9 Feeling sad     
10 Feeling that doing anything is a real effort     
11 Feelings of guilt or remorse     
12 Having nightmares or bad dreams     
13 I feel like a failure     
14 I feel like I'm being punished     
15 Loss of interest in sex     
16 Not enjoying things as much as before     



































Anxiety Questions 0 1 2 3 
1 Feeling anxious     
2 Feeling keyed up or on edge     
3 Feeling nervous     
4 Feeling restless     
5 Feeling tense     
6 Fidgety, I can't sit still     
7 Having nightmares or bad dreams     
8 High-strung or keyed up     
9 I find it hard to relax     
10 Worrying too much     
Mood Stability Questions 0 1 2 3 
1 Anger     
2 Angry outbursts     
3 Crying spells     
4 Easily agitated     
5 Easily annoyed     
6 Easily frustrated     
7 Elevated mood, euphoria     
8 Excitable     
9 Explosive     
10 Feeling irritable     
11 Feeling negative     
12 My moods change quickly     
13 Temper tantrums     
ADHD Questions 0 1 2 3 
1 Difficulty concentrating     
2 Difficulty paying attention     
3 Easily distracted     
4 Feeling restless     
5 Feeling scattered, disorganized     
6 Fidgety, I can't sit still     
7 Forgetful, I need constant reminding     
8 Impatient     
9 Impulsive, act without thinking     
10 Leaving things behind and having to go back to get them.      
11 Losing things     
12 Making careless mistakes     
13 Not finishing chores, homework or projects     
14 Overly active     







Neurological Signs/Symptoms 0 1 2 3 4 
1. Arm swing: Decreased       
2. Contortions/neck -arching back       
3. Gait: Imbalance/unsteady         
4. Gait: Shuffling         
5. Limb jerking/writhing        
6. Movement: Slowed         
7. Restlessness/pacing/can't sit still       
8. Rigidity/muscle pain or aches       
9. Tremor/shakiness         
10. jitteriness/jumpiness/nervousness       
11. fainting/dizziness/Upon standing       
12. seizures: increased         
13. tingling/numbness         
14. weakness/fatigue         
Psychological Signs/Symptoms 0 1 2 3 4 
1. Agitation          
2. Confusion          
3. Crying/feelings of sadness        
4. Drowsiness/Lethargy/Sedation       
5. Irritability          
6. Withdrawn          
7. attention/concentration difficulty       
8. morning "hangover"         
9. nightmares/vivid dreams        
10. perceptual: hallucinations/delusions       
11. sleep: excessive         







Letters of Permission 
10-20 system for EEG 
I, the copyright holder of this work, release this work into the public domain. This applies 
worldwide. In some countries this may not be legally possible; if so: 
I grant anyone the right to use this work for any purpose, without any conditions, unless 
such conditions are required by law. 
Wikipedia 
Monitoring of Side Effects Scale 
The MOSES (Monitoring of Side Effects Scale) is in the public domain so no official 
permission is required for its use.    
Chris Coleman, Ph.D. 
Department of Social and Health Services 
Clinical Director 
Division of Developmental Disabilities 
Neuropsych Questionnaire/CNSVS Neurocognitive Tests 
We are happy to help support academic research.    
To export the data, open up the application and click on Menu>Export and then select the 
files to be exported.  The data exports to a tab delimited file.  To get in excel, simply cut 
and paste from the notepad file.   
 Kind regards,  
Meghan Nolan 





EEG Frequency Pictorials 
This file is licensed under the Creative Commons Attribution-Share Alike 3.0 
Unported license. You are free: to share – to copy, distribute and transmit the work, to 
remix – to adapt the work. Under the following conditions: attribution – You must 
attribute the work in the manner specified by the author or licensor (but not in any way 
that suggests that they endorse you or your use of the work). Share alike – If you alter, 
transform, or build upon this work, you may distribute the resulting work only under the 
same or similar license to this one. This licensing tag was added to this file as part of the 
























2007-2012 Walden University, PhD in Clinical Psychology, GPA 3.9 
2008-2010 Behavioral Medicine Research and Training Foundation  
   Board Certified in Neurofeedback (BCN) 
2001-2003 University of Detroit Mercy, MA in Clinical Psychology, GPA 3.9 
   Summa Cum Laude graduate 
   Limited Licensed Psychologist, ID# 6301012513 
1997-2001 University of Detroit Mercy, BA in General Psychology, Major GPA 3.9 
  Summa Cum Laude graduate 
  Leadership Medallion Award 
 
CAREER EXPERIENCE: 
(6/10-6/11) Internship Student 
40 hours per week 
Community Consultation and Treatment, 
North Country Community Mental Health 
Duties include intake assessments, treatment planning, individual and group therapy, 
consultation with psychiatrists and medical director, and providing crisis intervention and 
assessments. Intern supervisor at one of the CMH clinics.  Facilitated an 8 session 
intervention for parents with children who have Autism/Asperger’s syndrome.  Group 
therapy for 6 adults with dual diagnoses: bipolar and substance abuse disorders. 
 
(1/09-6/10) Outpatient Therapist 
40 hours per week 
Community Consultation and Treatment, 
North Country Community Mental Health 
Duties include intake assessments, treatment planning, individual and group therapy, 
consultation with psychiatrists and medical director, and providing crisis intervention and 
assessments. Co-facilitated two 6 week interventions for a group of individuals with 
Autism/Asperger’s syndrome teaching psychosocial skills and conflict resolution. 
 
(10/05-1/09) Supports Coordinator/Psychologist 
40 hours per week 
Julie Moran, MSW, QMRP, Supervisor 





North Country Community Mental Health 
Duties include psychological evaluations for guardianship and treatment 
recommendations, individual therapy, behavioral approaches, consultation with 
psychiatrists and medical director, providing crisis intervention, coordinating and linking 
community and NCCMH services, establishing and monitoring treatment plans, 
advocating for the optimal level of multimodal services, and intake/annual assessments.  
Linked with multiple IEP meetings and coordinated with TBAISD Autism Specialist, 
School Psychologists, and School Social Workers. Co-facilitated three 6 week 
interventions for a group of individuals with Autism/Asperger’s syndrome teaching 
psychosocial skills and conflict resolution. 
 
(4/04-10/05) Contractual Psychologist 
32 hours per week 
Anne Kennedy, PhD, Supervisor 
Psychological Services Program, 
Detroit East, Inc. Community Mental Health Center 
Duties include facilitating a psychosocial skills/solution-focused group, individual 
therapy for adolescents and adults, conducting comprehensive psychological evaluations, 
and presenting continuing education (CE) workshops.  Left position to relocate in 
northern Michigan. 
 
(6/03-10/03) Practicum Student 
Steven Genden, PhD, Supervisor 
Adult Outpatient Program, 
Downriver Guidance Center 
Duties included administering intake assessments, conducting psychological evaluations, 
maintaining a small caseload, and managing case files.  Completed 400 hours and 
finished practicum requirements. 
 
(2/03-5/03) Practicum Student 
F. Edward Rice, PhD, Supervisor 
Children and Family Services, 
Northeast Guidance Center 
Duties included administering intake assessments, conducting psychological evaluations, 
and assisting in home based services.  Completed 200 hours and continued practicum at 
Downriver Guidance Center. 
 
(1/03-4/03) Student Therapist 
Susan Birndorf, PhD, Supervisor 
Outpatient Therapy Course, 
University of Detroit Mercy Psychology Clinic 
Duties included conducting short-term cognitive-behavioral therapy, providing session 







(10/01-5/03) Art Therapist Volunteer 
20 hours per week 
Sr. Nancyann Turner, Director 
Art Therapy Services, 
Capuchin Soup Kitchen 
Duties included utilizing art therapy techniques to help disadvantaged youth cope with 
stress through creating art. Supervised by a trained art therapist. 
 
PSYCHOLOGICAL ASSESSMENT/TESTING EXPERIENCE: 
(9/01-present) Completed many comprehensive psychological evaluations utilizing: 
Intelligence Tests: 
 Wechsler Nonverbal Scale of Abilities 
 Wechsler Adult Intelligence Scale 3rd Edition 
 Wechsler Abbreviated Scale of Intelligence 
 Wechsler Intelligence Scale for Children 4th Edition 
 Test of Nonverbal Intelligence 3rd Edition 
Neuropsychological Tests: 
 CNSVS Neurocognitive Test 
 Comprehensive Trail Making Test 
 Visual Motor Integration Test 
 Bender Visual-Motor Gestalt Test 
 Benton Visual Retention Test, Revised 
 Mini-Mental Status Examination 
 Verbal Fluency Test and Sentence Repetition/Memory 
 Repeatable Battery for Assessment of Neuropsychological Status 
 Quick Neurological Screening Test, 2nd Edition 
Achievement Tests: 
 Wechsler Individual Achievement Test, 2nd Edition 
 Wide Range Achievement Test, 3rd Edition 
 Test of Language Development, 2nd Edition 
 Peabody Picture Vocabulary Test, Revised 
 Slosson Oral Reading Test, 2nd Edition 
Checklists and Self-Reports: 
 Minnesota Multiphasic Personality Inventory 2nd Edition and Restructured Format 
 Achenbach Child Behavior Checklist and Teacher Report Form 
 Beck Youth Inventories, Self Report 
 Child Symptom Inventories, Teacher and Parent Checklists 
 Kovacs’ Children’s Depression Inventory 
 Conners Teacher and Parent Reports/Conners Adult ADHD Self and Observer 
Reports 
 Child and Adolescent Functional Assessment Scale 
 Adaptive Behavior Assessment System and Vineland Adaptive Behavioral Scales 
 Neuropsych Questionnaire Long and Short Form 








(3/12)  Suicide Prevention Workshop with local community organizations 
(6/11)  Autism Spectrum Disorder: Putting the Pieces Together 
(1/11) Child and Adolescent Functional Assessment Scales for the DD program 
(11/10)  Suicide Prevention Network Presentation to Charlevoix-Emmet ISD 
(10/10)  Michigan Association of Community Mental Health: Destigmatizing Autism 
(9/10) CMH Board Presentation: Evidenced-Based Practices for Autism 
(8/09) NCCMH Board Presentation: Social Skills Groups for Autism  
(8/08) Diagnostic and treatment interventions for autism at DD Conference 
(6/08) “Normal People Scare Me”-discussion on autism at Charlevoix Library 
(8/07) “Normal People Scare Me”-discussion on autism at DD conference 
(6/07) “Normal People Scare Me”-discussion on autism at Alden Library 
(3/05) Overview of a Comprehensive Psychological Evaluation: Case Study 
(2/05) Behavior and Self-Report Checklists at Detroit East, Inc. 
(2/05) Achievement Tests and Learning Disabilities, at Detroit East, Inc. 
(2/05) Neuropsychological Tests and Brain Functioning, at Detroit East, Inc. 
(2/05) Overview of Wechsler Intelligence Scale for Children, Fourth Edition 
(9/00-9/02) 20 Service-Learning presentations each semester on Servant Leadership 
 
NEWS ARTICLES: 
(11/1/02)   Detroit News, Metro Section C, by Margarita Bauza, “UDM’s 125th honors 
core values” 
(10/25/02) Michigan Catholic, Local News, by Audrey Sommers, “U of D Mercy 
celebrates 125 years” 
(1/24/01)   Varsity News, by Michael Lucido, “Racism on UDM campus: Breaking the 
Boundaries”  
